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 Emerging evidence suggests that environmental pollutants, including insecticides, are 
linked to excessive weight gain and altered glucose homeostasis. However, there is currently 
limited knowledge regarding the biochemical mechanisms by which exposure to insecticides 
contribute to obesity and its associated pathologies. We first studied the influence of fipronil (a 
phenylpyrazole family insecticide) on 3T3-L1 adipogenesis. Recently imidacloprid, a 
neonicotinoid insecticide, was reported to potentiate adipogenesis and insulin resistance in vitro. 
The current studies also determined the effects of imidacloprid exposure and its interaction with 
dietary fat in the development of adiposity and insulin resistance using both male and female 
C57BL/6J mice. Current results suggest that fipronil and imidacloprid alters adipogenesis and 
results in increased lipid accumulation via a AMPKα-mediated pathway in cell culture models. 
The current results also suggest that imidacloprid significantly promoted high fat diet-induced 
body weight gain and adiposity in mice (both males and females). In addition, imidacloprid 
treatment with high fat diet resulted in impaired glucose metabolism in male C57BL/6J mice. 
Consistently, there were significant effects of imidacloprid on key regulators of lipid and glucose 
metabolisms, including AMP-activated protein kinase-α (AMPKα) in the white adipose tissue and 









ACKNOWLEDGMENTS ............................................................................................................... v 
ABSTRACT .................................................................................................................................... vi 
LIST OF TABLES ......................................................................................................................... xii 
LIST OF FIGURES ...................................................................................................................... xiii 
CHAPTER 
1. INTRODUCTION .............................................................................................................. 1 
2. LITERATURE REVIEW ................................................................................................... 2 
2.1 Organic environmental pollutants introduction and classification................................ 2 
2.2 Insulin resistance and type 2 diabetes ........................................................................... 5 
2.3 Persistent organic pollutants (POP) and type 2 diabetes ............................................... 6 
2.4 Other pesticides and impaired glucose metabolism .................................................... 17 
2.5 Bisphenol A (BPA) and diabetes ................................................................................ 21 
2.6 Phthalates and diabetes ............................................................................................... 23 
2.7 Conclusion .................................................................................................................. 23 
3. FIPRONIL PROMOTES ADIPOGENESIS VIA AMPKα-MEDIATED 
PATHWAY IN 3T3-L1 ADIPOCYTES .......................................................................... 25 
3.1 Introduction ................................................................................................................. 25 
3.2 Materials and Methods ................................................................................................ 26 
3.2.1 Materials ..................................................................................................... 26 
3.2.2 3T3-L1 Culture ........................................................................................... 26 
ix 
 
3.2.3 Triglyceride quantification.......................................................................... 27 
3.2.4 mRNA expression analysis ......................................................................... 27 
3.2.5 Immunoblotting .......................................................................................... 28 
3.2.6 Statistical analyses ...................................................................................... 28 
3.3 Results ......................................................................................................................... 28 
3.3.1 Triglyceride measurements in 3T3-L1 adipocytes...................................... 28 
3.3.2 Influence of fipronil on genes controlling adipocyte differentiation 
and lipid metabolism ............................................................................... 29 
3.3.3 Effects of fipronil on the protein expression of regulators 
controlling adipogenesis ......................................................................... 30 
3.3.4 Effect of AMPKα activation on adipogenesis induced by fipronil ............. 32 
3.3.5 Influence of AMPKα activation on protein expression of regulators 
controlling adipogenesis ......................................................................... 33 
3.4 Discussion ................................................................................................................... 34 
4. IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY 
AND INSULIN RESISTANCE IN MALE C57BL/6J MICE .......................................... 38 
4.1 Introduction ................................................................................................................. 38 
4.2 Materials and Methods ................................................................................................ 40 
4.2.1 Materials ..................................................................................................... 40 
4.2.2 Animals and diet ......................................................................................... 41 
4.2.3 Serum parameters ....................................................................................... 42 
4.2.4 Insulin tolerance test ................................................................................... 42 
4.2.5 Glucose tolerance test ................................................................................. 43 
x 
 
4.2.6 Adipocyte size measurement ...................................................................... 43 
4.2.7 mRNA expression analysis ......................................................................... 44 
4.2.8 Immunoblotting .......................................................................................... 44 
4.2.9 Statistical analyses ...................................................................................... 45 
4.3 Results ......................................................................................................................... 45 
4.3.1 Imidacloprid promoted weight gain in high fat diet fed mice ..................... 45 
4.3.2 Influence of imidacloprid on tissue and organ weights .............................. 48 
4.3.3 Influence of imidacloprid on serum markers .............................................. 48 
4.3.4 Effects of imidacloprid on glucose homeostasis ......................................... 49 
4.3.5 Effects on mRNA levels of genes regulating lipid metabolism and 
AMPKα pathway in ................................................................................ 55 
4.3.6 Effects on expression of genes regulating lipid and glucose 
metabolism as well as AMPKα ............................................................... 58 
4.3.7 Effects on expression of genes regulating lipid and glucose 
metabolism in muscle ............................................................................. 59 
4.4 Discussion ................................................................................................................... 62 
5. IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY IN 
FEMALE C57BL/6J MICE AND ENHANCE ADIPOGENESIS IN 3T3-L1 
ADIPOCYTES VIA AMPKα-MEDIATED PATHWAY ................................................ 67 
5.1 Introduction ................................................................................................................. 67 
5.2 Materials and Methods ................................................................................................ 68 
5.2.1 Materials ..................................................................................................... 68 
5.2.2 Animals and diet ......................................................................................... 69 
5.2.3 Serum parameters ....................................................................................... 70 
5.2.4 Insulin tolerance test ................................................................................... 70 
5.2.5 Glucose tolerance test ................................................................................. 71 
xi 
 
5.2.5 Adipocyte size measurement ...................................................................... 71 
5.2.6 mRNA expression analysis ......................................................................... 72 
5.2.7 Immunoprecipitation and immunoblotting ................................................. 72 
5.2.8 Cell culture .................................................................................................. 72 
5.2.9 Determination of cellular oxidative status .................................................. 73 
5.2.10 Statistical analyses .................................................................................... 73 
5.3 Results ......................................................................................................................... 74 
5.3.1 Imidacloprid enhanced body weight gain and adipocyte size in high 
fat diet-fed mice ...................................................................................... 74 
5.3.2 Effects of imidacloprid on organs and tissue weights................................. 76 
5.3.3 Effects of imidacloprid on serum markers .................................................. 79 
5.3.4 Influence of imidacloprid on glucose homeostasis ..................................... 79 
5.3.4 Effects of imidacloprid on AMPKα pathway and TNFα in white 
adipose tissue .......................................................................................... 79 
5.3.4 Effects of AMPKα activation on imidacloprid induced 
adipogenesis ............................................................................................ 82 
5.3.5 Effects of imidacloprid on insulin signaling pathway in C2C12 
myotubes ................................................................................................. 83 
5.4 Discussion ................................................................................................................... 85 
6. FUTURE DIRECTIONS .................................................................................................. 89 
APPENDIX: PUBLICATION ....................................................................................................... 92 
BIBLIOGRAPHY .......................................................................................................................... 92 
xii 
 
   
LIST OF TABLES 
Table Page 
 
2.1. Summary of epidemiological  and clinical studies of persistent organic pollutants 
(POP) on risk of diabetes in human. ........................................................................... 10 
 
2.2. Summary of human studies of other pesticides on risk of diabetes. ....................................... 19 
 
2.3. Summary 1of human studies of bisphenol A on risk of diabetes. ........................................... 22 
 
2.4. Summary of human studies of phthalate on risk of diabetes. ................................................. 24 
 
4.1. Composition of diet................................................................................................................. 42 
 
4.2. Organ Weights (% of body weight) ........................................................................................ 51 
 
4.3. Serum Parameters ................................................................................................................... 52 
 
5.1. Organ Weights (% of body weight) ........................................................................................ 77 
 















LIST OF FIGURES 
Figure Page 
3.1. Fipronil treatment increased triglyceride accumulation in 3T3-L1 adipocytes. ..................... 30 
 
3.2. Effects of fipronil on gene expression of molecular mediators of adipogenesis. ................... 31 
 
3.3. Effects of fipronil on protein levels of molecular mediators of adipogenesis. ....................... 32 
 
3.4. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased 
fat accumulation induced by fipronil. ......................................................................... 33 
 
3.5. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased 
expression of C/EBPα, ACC and the decreased expression of PAMPKα, 
PACC induced by fipronil. ......................................................................................... 34 
 
4.1. Effects of imidacloprid on body weight, body weight gain and food intake. Mice 
were fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 and 
6 mg/kg bw/day) imidacloprid for 12 weeks. ............................................................. 47 
 
4.2. Effects of imidacloprid on adipocyte size. Mice were fed with low fat diet or high fat   
diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 
12 weeks. .................................................................................................................... 53 
 
4.3. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance 
test (GTT) (D, E, F) and insulin level determination with serum from GTT 
(G, H, I) as the area under the curve (AUC). ............................................................. 54 
 
4.4. Effects of imidacloprid on HOMA-IR score. Mice were fed with low fat diet or high 
fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid 
for 12 weeks. .............................................................................................................. 55 
 
4.5. Effects of imidacloprid on molecular target genes involved in lipid metabolism and 
inflammation in white adipose tissue. ........................................................................ 58 
 
4.6. Effects of imidacloprid on molecular target genes regulating lipid and glucose 




4.7. Effects of imidacloprid on markers regulating lipid and glucose metabolism in 
muscle......................................................................................................................... 62 
 
5.1. Effects of imidacloprid on body weight, body weight gain, adipocyte size and food 
intake. ......................................................................................................................... 75 
 
5.2. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance 
test (GTT) (D, E, F) as determined as the area under the curve (AUC) and 
HOMA-IR (G).. .......................................................................................................... 81 
 
5.3. Effects of imidacloprid on AMPKα pathway and TNFα expression in the white 
adipose tissue. ............................................................................................................. 82 
 
5.4. Influence of AMPKα activation on adipogenesis induced by imidacloprid in 3T3-L1 
adipocytes. .................................................................................................................. 83 
 











 The incidence of overweight and obesity has increased dramatically in recent decades and 
become one of the leading health problems all over the world [1].  Lifestyle and dietary changes 
alone cannot account for the dramatic rise of overweight and obesity worldwide [2]. An 
increasing number of literatures have shown the relationships between exposure to environmental 
pollutants, including pesticides, and obesity in humans and animals [3-7]. However, there is 
currently limited knowledge regarding the biochemical mechanisms, by which exposure to 
pesticides contribute to obesity and its associated pathologies. Thus, understanding these 
mechanisms will be critical in providing background knowledge that may guide future 
mechanistic and/or epidemiological studies, which will lead to development of effective strategies 
for treating and/or preventing these diseases in the future [8].  
 Our previous studies reported that imidacloprid, a neonicotinoid insecticide, promotes 
adipogenesis in 3T3-L1 adipocytes and induces insulin resistance in C2C12 myotubes [7, 9]. 
However, it is not known whether fipronil (phenylpyrazole family insecticide) could also 
promotes adipogenesis and if imidacloprid exposure alone or in combination with a known 
inducer of obesity and insulin resistance, such as high-fat diet, will exacerbate obesity and insulin 
resistance symptoms in mice model. Thus, the current study was to determine if fipronil promotes 
adipogenesis in 3T3-L1 adipocytes and if chronic exposure to low levels of imidacloprid promote 
metabolic disorders characterized by adiposity, dyslipidemia, hyperglycemia, and insulin 







2.1 Organic environmental pollutants introduction and classification 
 This chapter will focus on organic environmental pollutants, including persistent organic 
pollutants (POPs), pesticides (not on POPs Stockholm Convention list), bisphenol A and 
phthalates. POPs represent a diverse range of chemicals, which are persistent in the body and the 
environment [10]. POPs bio-accumulate in animal and human with potentially significant impacts 
on human health and the environment [10]. A wide variety of chemicals were included in the 
POPs category, including organochlorine insecticides, polychlorinated biphenyls (PCBs), dioxin-
like compounds, brominated flame retardants (BFRs), and perfluorinated compounds [10]. 
Organochlorine insecticides consist of DDT, dieldrin, heptachlor, chlordane, lindane, and 
toxaphene, all of which have chlorinated hydrocarbon structures [11]. Organochlorine 
insecticides have very low water solubility and very high lipid solubility [11], thus extremely 
resistant to degradation and persistent in the environment [11]. Organochlorine insecticides are 
mainly divided into two groups: DDT-type insecticides and chlorinated alicyclic insecticides. The 
mechanism of insecticide action of DDT-type insecticides is by preventing the closing of sodium 
gates of the axon, resulting in persistent leakage of Na+ ions through the nerve membrane and 
repetitive firing of action potentials [11]. By comparison, chlorinated alicyclic insecticides is 
purported to bind with gamma-aminobutyric acid (GABA) chloride ionophore complex, thus 
resulting in hyper-excitation [11]. DDT was once one of the most popular insecticides used 
against insects during 1940s to 1960s [12]. Dichlorodiphenyldichloroethylene (DDE), a major 
metabolite of DDT, is also used as an insecticide. Due to their potential toxicity to plants, animals 
and persistency in the environment, most developed countries including USA have banned the 
use of DDT and other organochlorine insecticides in 1970s [12]. However, DDT and other 
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organochloride residues continue to be found in humans and mammals many years after the use 
have been limited and DDT is still used in sub-Saharan Africa and India to fight malaria [13, 14].  
 A polychlorinated biphenyl (PCB) is an organic chlorine compound with the formula 
C12H10−xClx. PCBs were once widely used as dielectric and coolant fluids in electrical 
apparatus and in heat transfer fluids [15]. PCBs consist of 209 isomers and congeners with 
different numbers and positions of chlorine atoms substituted on the biphenyl moiety [15]. Some 
PCBs share a structural similarity and toxic mode of action with dioxin through aryl hydrocarbon 
(AH) receptor, which regulates the expression of many genes [16]. Other toxic effects such as 
endocrine disruption (notably blocking of thyroid system functioning) and neurotoxicity are 
known [17]. PCBs are persistent in the environment, bio-accumulate and bio-magnify in the food 
chain, due to their lipophilicity [15]. Exposure to PCBs have been reported to induce biochemical 
and morphological changes in cells and laboratory animals that are linked to neurological and 
behavioral dysfunctions [15]. 
 Dioxin-like compounds, including polychlorinated dibenzo-p-dioxins (PCDDs), 2,3,7,8-
tetrachlorodibenzodioxin (TCDD), polychlorinated dibenzofurans (PCDFs), mostly come from 
by-products of industrial processes, such as bleaching paper pulp, pesticide manufacture, as well 
as waste incineration [18, 19]. Dioxin-like compounds act through aryl hydrocarbon (AH) 
receptor, which is present in all cells [20-23]. The receptor is a transcription factor involved in 
expression of a variety of genes [20]. Low doses of dioxin-like compounds exposure have 
developmental effects, such as palate and hydronephrosis [24]. 
 Brominated flame retardants (BFRs), which have an inhibitory effect on combustion 
chemistry, are widely used in global industry, and many of them are still produced and used in 
large volumes [25]. Due to this, several BFRs are found in both wildlife as well as in humans [25]. 
Polybrominated diphenyl ethers (PBDEs), polybrominated biphenyl (PBB), and brominated 
cyclohydrocarbons are three major types of BFRs [26]. Some PBDEs are lipophilic and bio-
accumulate in fatty tissue and PBDEs have been detected in people all over the world [27].  
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 Perfluorinated compounds (PFC) are organofluorine compounds with carbon-fluorine 
bonds, C-C bonds, and other heteroatoms. These fluorinated chemicals are used in various of 
consumer goods from non-stick kitchenware to waterproof clothing [28]. Two PFCs, 
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), have been found to be 
persistent and toxic, which pose a global contamination problem [29]. In animals, some PFCs can 
disrupt normal endocrine activity, reduce immune function, and cause adverse effects on multiple 
organs, including the liver and pancreas [30, 31]. 
 Other insecticides, which are not included in the POPs categories, include pyrethroids, 
organophosphorus insecticides, carbamates, and neonicotinoids in the current review. Pyrethroids 
are synthetic compounds similar to the natural insecticide pyrethrins in the flowers pyrethrums 
(Chrysanthemum cinerariaefolium and C. coccineum). Pyrethroids can prevent the closure of 
voltage-gated sodium channels in axonal membranes, causing over-excitation of the neuron [12, 
32]. Pyrethroids are developed in the 1960s and 1970s and are known to be effective against 
insects with low mammalian toxicity. At present, 13 pyrethroids in more than 3,500 registered 
formulations are widely used in the United States to control insect pests in agriculture, animal 
protection, and public health [33].  
 Organophosphorus insecticides are the largest insecticide class in the world in 1980s, 
occupying about 70% of world insecticides market in 1987. Organophosphorus insecticides 
inactivate the enzyme acetylcholinesterase, causing over-excitation of the neurons [34]. However, 
the use of organophosphorus insecticides is decreasing due to their environmental persistence [35, 
36]. A carbamate is an organic compound derived from carbamic acid (NH2COOH) with 
carbamate ester and carbamic acids as functional groups. Carbamates can also inhibit the enzyme 
acetylcholinesterase (AChE), thus leading to over-excitation of the neurons, but the inhibition of 
AChE is reversible and carbamates are rapidly metabolized in animals [37, 38].  
 Neonicotinoids are a relatively new class of insecticides with similar structure as nicotine. 
Neonicotinoids are agonists to nicotinic acetylcholine receptors (nAChRs), which can stimulate 
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these receptors at low dose, while block these receptors in high dose, leading to paralysis or death 
[39]. They have high affinity for insect nAChRs, but not for vertebrate nicotinic acetylcholine 
receptor, thus having selective toxicity for insects [40, 41]. Neonicotinoids are the fastest growing 
class of insecticides, representing ~27% of the global insecticide market in 2010, making it the 
largest single insecticide class on the market [42]. Imidacloprid and two other neonicotinoids 
were banned by the European Commission in 2013 due to their potential risk for the decrease of 
bee populations [43]. 
 Bisphenol A (BPA) belongs to a group of phenols, which have hydroxyl residue bounded 
to aromatic ring. BPA is used in various products for everyday use, including water-pipes, 
electronic equipment, paper, as well as food packaging materials. It can bind to several kinds of 
receptors, including estrogen, androgen, aryl hydrocarbon and peroxisome proliferator-activated 
receptors that are related to endocrine and other systems of the body [44].  
 Phthalates are esters of phthalic acid and are mainly used as plasticizers. They are present 
in a variety of products, including food packaging, building materials, clothing and medical 
devices [45]. Phthalates are not covalently bounded to the plastic matrix, thus leaching out to the 
external environment easily. Although most phthalates show very low-acute toxicity, the 
reproductive system is susceptible to these compounds, thus European Union started to ban the 
use of reproductive toxic phthalates in toys and childcare articles in 2005 [45]. 
2.2 Insulin resistance and type 2 diabetes 
 Obesity is now endemic and the prevalence of type 2 diabetes (T2D), which is closely 
associated with obesity, is also on the rise [46]. Type 2 diabetes also known as non-insulin 
dependent diabetes, is the most common form of diabetes [47]. Insulin resistance, a hallmark of 
type 2 diabetes, is a pathological condition, in which cells fail to respond to insulin [48]. Insulin 
resistance is associated with many factors, which include decreased expression or tyrosine 
phosphorylation of insulin receptor and insulin receptor substrate, decreased expression or 
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translocation of glucose transporters, and abnormal expression or activities of a variety of 
enzymes [49]. 
 Adipose tissue has a very important role in insulin resistance. Circulating free fatty acids 
(FFA) obtained from adipocytes have been suggested to promote insulin resistance by inhibiting 
insulin signaling, glucose uptake, glycogen synthesis, and glucose oxidation, as well as by 
elevating hepatic glucose output [50]. Studies also revealed that diacylglycerol and ceramides 
accumulation in muscle and liver can activate Novel protein kinase C Isoforms (nPKCs), thus 
causing insulin resistance [46]. Overexpression of hepatic lipoprotein lipase or fatty acid 
translocase (CD36) promotes hepatic lipid accumulation and can lead to insulin resistance [46].  
 Adipose tissue also produces and secretes adipokines, which may significantly affect 
lipid and glucose metabolism as well as energy expenditure. Compared to lean subjects, in obese 
rodents and humans, tumor-necrosis factor-α (TNF- α) expression is increased and has been 
reported to induce serine phosphorylation of IRS-1, resulting in reduced insulin receptor kinase 
activity and insulin responsiveness [51]. The mRNA expression of adiponectin, another adipokine 
secreted by adipose tissue that sensitize insulin responses, is also decreased in obese humans and 
mice [52]. Acute treatment of mice with this adipokine alleviates insulin resistance, decreases 
plasma FFAs and triglycerides content of muscle and liver, as well as increases expression of 
genes involved in fatty-acid oxidation and energy expenditure [52]. In addition, leptin produced 
by adipose tissue acts on its receptors in the central nervous system and other tissues to regulate 
food intake and energy expenditure [53]. Leptin deficiency or resistance are known to link insulin 
resistance, as proven by administration of exogenous leptin improves glucose tolerance and 
insulin sensitivity [53-55]. 
2.3 Persistent organic pollutants (POP) and type 2 diabetes 
Numerous studies have reported the potential association between POP exposure and impaired 
glucose metabolism or type 2 diabetes (summarized in Table 2.1). In one study, adipose tissue 
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concentrations of POPs were suggested to provide a suitable estimation of cumulative internal 
exposure to POPs, while serum concentrations of POPs might be a good predictor of point 
exposure [56]. There were a number of publications linking 2,2-bis (4-chlorophenyl) -1,1-
dichloroethylene (p,p'-DDE), 2,2-bis (4-chlorophenyl)-1,1-dichloroethane (p,p'-DDD), two 
metabolites of 2,2-bis (4-chlorophenyl)-1,1,1-trichloro-ethane (p,p'-DDT) and increased risk of 
diabetes [5, 56-75]. However other studies didn’t find the association between DDE exposure and 
risk of diabetes [76-83]. Two studies reported increased plasma DDE concentrations in diabetic 
individuals than no-diabetic individuals, however, they failed to prove significant association 
between DDE and diabetes [76, 77]. It was suggested that the higher plasma level of DDE might 
be due to greater lipolysis rate in diabetic individuals compared to non-diabetic individuals [76, 
77].   
 Similarly, DDT was related to increased risk of diabetes in several human studies [58, 60-
62, 67-69, 84, 85]. Two studies reported that low-dose background exposure of DDT was 
strongly associated with the prevalence of type 2 diabetes in Asia, which suggested that Asians 
might be more susceptible to adverse effects of DDT than other races [60, 62]. Serum 
concentrations of POPs, including DDT, were further related to decreased glucose utilization and 
higher lipid oxidation in non-diabetic individuals and the prevalence of prediabetes and diabetes 
in Eastern Slovakia [67].  
 Several studies reported the potential link between hexachlorobenzene (HCB) and 
diabetes [60, 63, 67, 69, 70, 77, 81, 83]. One prospective study reported that childhood (8-9 years 
old) HCB exposure was associated with higher odds of insulin resistance when measured at 10-13 
years old [81]. Although one study reported positive correlation between adipose tissue HCB and 
diabetes [56], other studies didn’t find the significant association between HCB exposure and 
diabetes [5, 56, 58, 76, 79].  
 β-Hexachlorocyclohexane (β-HCH) was reported to be associated with insulin resistance 
or diabetes in many studies [56, 58, 60, 61, 68, 81, 86], while others reported no significant 
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association of β-HCH with diabetes or insulin resistance [5, 67, 76, 77, 79, 83, 87, 88]. Similarly, 
γ-hexachlorocyclohexane (γ-HCH) was reported to be positively associated with diabetes in one 
study [89],  but not others [5, 79].  
 Chlordane and its metabolite oxychlordane as well as trans-nnonachlor were linked to 
increased risk of diabetes [58, 60, 61, 74, 79, 85, 87, 90, 91]. However, the other studies didn’t 
support these potential linkages [5, 76, 78, 83, 88]. Similarly, there are limited human studies 
reported the association between heptachlor, heptachlor epoxide (a metabolite of heptachlor), 
mirex or aldrin and increased risk of diabetes [60, 61, 63, 79, 82, 92, 93], although three studies 
didn’t support the association of mirex or aldrin with diabetes [5, 61, 76].  
 Polychlorinated biphenyls (PCB) were intensively studied and reported to be associated 
with increased risk of diabetes [56, 57, 63, 65, 66, 69, 70, 73, 74, 77, 79, 90, 94-97], while others 
reported no association between PCBs and diabetes [76, 78, 80, 86, 98, 99]. Dioxins, including 
hexachlorodibenzo-p-dioxin (HxCDD), 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), 
1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) and polychlorinated dibenzodioxins 
(PCDDs) were suggested to be positively associated with risk of diabetes in a few studies [74, 
100, 101]. While no association was reported between HxCDD and risk of diabetes in one study 
[86]. 
  Some studies reported a positive association between polybrominated diphenyl ethers 
(PBDEs) and diabetes [73, 102], while another study didn’t find such positive association [76].   
Polybrominated biphenyls (PBBs) were reported to be positively associated with diabetes [79, 
102], but not in the other study [5]. 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47), 2,2’,4,4’,5,5’-
hexabromodiphenyl ether (BDE153) or perfluoroalkyl substances were nor found to have positive 
relationship with risk of diabetes [78, 80, 90]. 
 As shown in Table 2.1, it may be sufficient to conclude for a positive correlation between 
certain POPs exposure and risk of diabetes, especially for DDT, DDE, HCB and PCB. However, 
most of these are cross-sectional studies, which have their limitation in establishing a clear causal 
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relationship. Thus, more prospective human studies are needed to clarify the causal relationship 
between POPs exposure and diabetes.   
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Table 2.1. Summary of epidemiological  and clinical studies of persistent organic pollutants 
(POP) on risk of diabetes in human. 
Study design 
Subject Risk of 
diabetes 
Other comments Ref. 
Description Gender 
Organochlorines      
2,2-bis (4-chlorophenyl)-1,1-dichloroethylene (p,p'-DDE) 
Case-control Sweden F ×  [83] 
Cross-section Sweden F + M ↑  [75] 
Cross-section USA  F + M ↑  [74] 
Cross-section USA  
Native Americans   
F + M ↑  [63] 
Cross-section USA  
Mexican 
Americans   
F + M ↑  [58] 
Cross-section USA F + M ↑  [88] 
Cohort Sweden 
Fishermen’s wives 




F + M ↑ Self-reported [57] 
Case-control Sweden 
50-59 old women 
F ↑  [64] 
Prospective USA, Great Lakes 
sport fish 
consumers 
F + M ↑  [72] 
Cross-section USA  F + M ↑  [61] 
Case-control USA F + M ×  [79] 
Case-control Korea  F + M ↑ Self-reported [60] 
Cross-section Slovak Republic F + M ↑  [67] 
Prospective USA F + M ↑  [5] 
Prospective Sweden, 70 years-
old 
F + M ×  [80] 




Cross-section Spain    F + M ×  [77] 
Cross-section Spain  F + M ↑  [56] 
Cross-section Canada 
First nation 




community   
Case-control Benin F + M ↑ ↑ Blood DDE [68] 
Prospective Russia M × ↓ Leptin [81] 
Cross-section Belgium  F + M ↑  [65] 
Cross-section Slovakia F + M ↑  [71] 
Cross-section Thailand F + M ↑  [59] 
Cross-section Saudi Arabia    F + M ↑ ↑ Insulin [62] 
Prospective USA, Great Lakes 
sport fish 
consumers 
F + M ↑  [73] 
Prospective Belgium F + M ↑ Only in M [70] 
Cohort France, Newborns  F + M × ↓ insulin 
↓ adiponectin 
[82] 
Cohort Canada  F ×  [78] 
2,2-bis (4-chlorophenyl)-1,1,1-trichloro-ethane (p,p'-DDT) 
Cross-section USA  
Mexican 
Americans     
F + M ↑ Self-reported [58] 
Cross-section USA  F + M ↑  [84] 
Cross-section USA F + M ×  [87] 
Cross-section USA  F + M ↑  [61] 
Cross-section USA F + M ×  [79] 
Case-control Korea  F + M ↑  [60] 
Cross-section Slovak Republic F + M ↑  [67] 
Prospective USA  F + M ×  [5] 
Cross-section Denmark F + M ↑ ↓ Glucose 
oxidation 
[69] 
Cross-section Spain    F + M ×  [77] 
Case-control Benin F + M ↑ ↑ Blood DDT [68] 
Cross-section Korea   F + M ↑  [85] 
Cross-section Saudi Arabia   F + M ↑ ↑ TG [62] 
2,2-bis (4-chlorophenyl)-1,1-dichloroethane (p,p'-DDD) 
Case-control Korea  F + M ↑  [60] 
2,2-bis(o,p-chlorophenyl)-1,1,1-trichloroethane (o,p'-DDT) 
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Case-control Korea  F + M ↑  [60] 
2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1,1-trichloroethane; hexachlorobenzene (HCB) 




F + M × Self-reported [58] 
Cross-section USA 
Native Americans   
F + M ↑  [63] 
Cross-section USA F + M ×  [79] 
Case-control Korea  F + M ↑  [60] 
Cross-section Slovak Republic F + M ↑  [67] 
Cross-section Denmark F + M ↑ ↓ Glucose 
oxidation 
[69] 
Prospective USA  F + M ×  [5] 
Cross-section Spain  F + M ↑  [77] 
Cross-section Spain   F + M ×  [56] 
Cross-section Canada 
First nation 
community   
F + M × ↑ Blood HCB [76] 
Prospective Russia M ↑  [81] 
Prospective Belgium F + M ↑  [70] 
β-Hexachlorocyclohexane (β-HCH) 
Case-control Sweden F ×  [83] 
Cross-section USA 
Mexican 
Americans   
F + M ↑ Self-reported [58] 
Cross-section USA F + M ×  [88] 
Cross-section USA F + M ×  [87] 
Cross-section USA  F + M ↑  [61] 
Case-control USA  F + M ×  [79] 
Case-control Korea  F + M ↑  [60] 
Cross-section Slovak Republic F + M ×  [67] 
Cross-section Belgium F + M ↑  [86] 
Prospective USA   F + M ×  [5] 
Cross-section Spain  F + M ×  [77] 
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Cross-section Spain  F + M ↑  [56] 
Cross-section Canada 
First nation 
community   
F + M × ↑ Blood β-HCH [76] 
Case-control Benin F + M ↑ ↑ Blood β-HCH [68] 
Cross-section Saudi Arabia F + M ↑  [89] 
Prospective Russia M ↑  [81] 
ɣ-Hexachlorocyclohexane (ɣ-HCH) 
Case-control USA  F + M ×  [79] 
Prospective USA  F + M ×  [5] 
Cross-section Saudi Arabia F + M ↑  [89] 
Chlordane & oxychlordane 
Case-control Sweden F ×  [83] 
Cross-section USA  F + M ↑  [74] 
Cross-section USA  
Mexican 
Americans   
F + M ↑ Self-reported [58] 
Cross-section USA F + M ×  [88] 
Cross-section USA F + M ↑  [87] 
Prospective USA, pesticide 
applicators and 
spouses 
F + M ↑  [91] 
Cross-section USA  F + M ↑  [61] 
Case-control USA  F + M ↑  [79] 




F + M ↑  [90] 
Prospective USA  F + M ×  [5] 
Cross-section Canada 
First nation 
community   
F + M × ↑ Oxychlordane 
in diabetic 
[76] 
Cohort Canada  F ×  [78] 
Trans-nonachlor 
Case-control Sweden F   ×  [83] 
Cross-section USA  F + M ↑  [74] 
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Cross-section USA  
Mexican 
Americans   
F + M ↑ Self-reported [58] 
Cross-section USA F + M ×  [88] 
Cross-section USA F + M ↑  [87] 
Cross-section USA  F + M ↑  [61] 
Cross-section USA F + M ↑   [79] 
Case-control Korea  F + M ↑  [60] 
Prospective USA F + M ×  [5] 
Heptachlor 
epoxide 
     
Cross-section USA  F + M ↑  [61] 
Cross-section USA  F + M ↑  [92] 
Case-control Korea  F + M ↑  [60] 
Cross-section Korea F + M ↑  [85] 
Case-control Korea  F + M ×  [93] 
Heptachlor      
Prospective USA, pesticide 
applicators and 
spouses 
F + M ↑  [91] 
Mirex      
Cross-section USA  
Native Americans    
F + M ↓  [63] 
Cross-section USA  F + M ×  [61] 
Case-control USA  F + M ↑  [79] 
Case-control Korea  F + M ↑  [60] 




F + M × ↑ Blood mirex [76] 
Aldrin      
Prospective USA, pesticide 
applicators and 
spouses 
F + M ↑  [91] 
Polychlorinated biphenyls (PCBs) 
Cross-section USA  F + M ↑  [74] 
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Cross-section USA 
Native Americans   
F + M ↑  [63] 
Cross-section USA   F + M ↑  [84] 
Cross-section USA  F + M ↑  [94] 
Cross-section USA  F + M ↑  [87] 
Cohort Sweden 
Fishermen’s wives 
F ↑ Self-reported [66] 
Cross-section Denmark F + M ×  [99] 




F + M ↑ Self-reported [57] 
Case-control USA  F + M ↑  [79] 




F + M ↑  [90] 
Cross-section Belgium F + M ×  [86] 
Prospective Sweden, 70 years-
old 
F + M ×  [80] 
Cross-section Japan F + M ↑ PCB 146 & 180 [98] 
Cross-section Japan F + M ↓  PCB 163,164 & 
170 
[98] 
Cross-section Denmark F + M ↑ ↓ Glucose 
oxidation 
[69] 
Cross-section Spain  F + M ↑  [77] 
Cross-section Spain  F + M ↑  [56] 
Cross-section Canada   
First nation 
community 
F + M × ↑ Blood PCBs in 
diabetic 
[76] 
Cross-section Belgium  F + M ↑  [65] 
Cross-section USA  F + M ↑  [95] 
Cross-section Korea  F + M ↑  [85] 
Cross-section Korea F + M ↑ ↓ Adiponectin [103] 
Case-control USA  F + M ↑  [97] 
Prospective USA, Great Lakes 
sport fish 
consumers 
F + M ↑  [73] 
Prospective Belgium F + M ↑  [70] 
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Cohort Canada  F ×  [78] 
Dioxin      
Hexachlorodibenzo-p-dioxin (HxCDD) 
Cross-section USA  F + M ×  [84] 
Cross-section Taiwan F + M ↑  [100] 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
Prospective USA, Vietnam 
veterans 
F + M ↑  [101] 
1,2,3,4,6,7,8-Heptachlorodibenzo-p-dioxin (HpCDD) 
Cross-section USA  F + M ↑  [74] 
1,2,3,4,6,7,8,9-Octachlorodibenzo-p-dioxin (OCDD) 
Cross-section USA  F + M ↑  [74] 
Polychlorinated dibenzodioxins (PCDDs) 
Cross-section USA  F + M ↑  [74] 
Brominated flame retardants (BFRs) 
Polybrominated diphenyl ethers (PBDEs) 
Cross-section USA F + M ↑  [102] 
Cross-section Canada 
First nation 
community   
F + M × ↑ Blood PBDE47 
in diabetic 
[76] 
Prospective USA, Great Lakes 
sport fish 
consumers 
F + M ↑  [73] 
Polybrominated biphenyl (PBB) 
Cross-section USA F + M ↑  [102] 
Case-control USA  F + M ↑  [79] 
Prospective USA  F + M ×  [5] 




F + M ×  [90] 
Prospective Sweden, 70 years-
old 
F + M ×  [80] 
Perfluorinated compound (PFC) 
Perfluorooctanoic acid (PFOA) 
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Cohort Canada  F ×  [78] 
Perfluorooctane sulfonate (PFOS) 
Cohort Canada  F ×  [78] 
Perfluorohexane sulfonate (PFHxS) 
Cohort Canada  F ×  [78] 
F, female; M, male; TG, triglyceride. 
↑, increase; ×, no association. 
 
2.4 Other pesticides and impaired glucose metabolism 
 Compared to the large amount (> 70) of human studies about the influence of POPs on 
impaired glucose metabolism, the studies of other pesticides-that’s not considered as POPs, on 
impaired glucose metabolism are relatively limited (summarized in Table 2.2). In general, 
subjects with pyrethroid exposure tend to have higher prevalence of abnormal glucose regulation, 
which might have implications in the development of type 2 diabetes. Two studies reported the 
positive associations of pyrethroid occupational exposures and abnormal glucose regulation [104, 
105]. A paper in 2008 reported that two pyrethroids (allethrin and prallethrin) exposure by 
inhalation significantly elevated the plasma glucose levels in exposed subjects [106]. There is a 
case report of hyperglycemia after intravenously injection of an unknown amount of a mixture of 
chlorpyrifos and cypermethrin [107].  However, others didn’t find significant effects of 
permethrin on ‘self-reported diabetes’, which is the limitation of the study [91].  
 Several studies reported the potential correlation between organophosphorous and 
impaired glucose metabolism, which is summarized in Table 2.2. Farmers and their families were 
reported to have hyperglycemia or higher HOMA-IR after exposure to malathion [108-111]. One 
study reported that exposure to parathion, malathion, and diazinon was associated with 
pancreatitis accompanied with hyperglycemia [111]. A 15-year old girl who intentionally 
consumed overdose of unspecified organophosphorous pesticide was found to have elevated 
glucose level as high as 336 mg/dl [112]. Another cohort study reported that urinary 
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dialkylphosphate metabolites of organophosphate pesticides were associated with increased 
insulin levels, though insulin resistance was not linked to dialkylphosphate metabolites of 
organophosphorous [82]. However, others didn’t find the association of other organophosphorous 
and diabetes, such as reverse associations with gestational diabetes mellitus and impaired glucose 
tolerance during pregnancy [78]. 
 Overall, there are human studies linking pesticides exposure to diabetes, which are shown 
in Table 2.2, but more human studies, especially prospective studies, are still needed to find the 
causal relationship. More animal studies can also be a valuable tool to understand the underlying 
mechanisms between these pesticides and diabetes.         
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Table 2.2. Summary of human studies of other pesticides on risk of diabetes.  
Study design 






Pyrethroids      
Allethrin & prallethrin     
Controlled trial India  M N/A ↑ Glucose [106] 




F + M N/A Self-reported [91] 




F + M ↑ ↑ BMI [104] 




M   ↑  [105] 
Chlorpyrifos & cypermethrin     
Case report Morocco  M N/A ↑ Glucose [107] 
Organophosphorus      
Malathion      
Case report 
Canada 
A woman and her 
son 
F + M N/A ↑ Glucose [108] 
Cross-section 
UDA, wives of 
farmers 
F ×    [113] 
Cross-section Egypt, farmers M ↑ ↑ Insulin  [109] 
Parathion, malathion & diazinon 





Cross-section USA F  ↑  [113] 
Diazinon & phorate  
Cross-section 
UDA, wives of 
farmers 
F     [113] 
Unspecified &mixrure 
Cross-section Turkey F + M N/A ↑ Glucose [114] 
Cross-section Iran, farmers F + M ↑ ↑ Glucose [110] 
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F, female; M, male. 
↑, increase; ×, no association; N/A, not applicable. 
 
  
Case report India F N/A ↑ Glucose [112] 
Cohort France, newborns  F + M N/A ↑ Insulin [82] 










F + M ↑  [91] 
Turbufos      
Cross-section 
USA, wives of 
farmers 
F ×   [113] 
Carbamates      
Unspecified      
Prospective Israel, children F + M N/A   [111] 
Carbaryl & carbofuran     
Cross-section 
USA, wives of 
farmers 
F 
× Carbaryl      
 ↑ Carbofuran 
  [113] 
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2.5 Bisphenol A (BPA) and diabetes 
 BPA has been reported to be positively associated with diabetes, which are summarized 
in Table 2.3. Positive association of urinary BPA with diabetes based on US National Health and 
Nutrition Examination Survey (NHANES) was reported in five studies [115-119], in particular, 
the association between BPA and prediabetes was stronger in obese people [117]. It is important 
to point out that individuals with higher BMI, who are more likely to have diabetes, might also 
have higher consumption of food contaminated with BPA, thus, might having higher levels of 
BPA [117]. Similarly, it was also suggested that higher level of BPA could potentially be linked 
to sugar beverages in plastic bottles and intake of sugar beverages might have complications in 
obesity and diabetes [120]. However, there are three studies not supporting the association of 
BPA with diabetes [121-124], including no positive association of BPA exposure during 
pregnancy and gestational diabetes [122, 123], although the studies have a limited sample size or 
the urinary BPA concentration was substantially lower than other pregnancy cohort. In summary, 
it is highly likely that there is a positive relationship between BPA and diabetes. However, 
several questions, including whether sugar beverages, BPA, or their interaction are the main 
causes of increased risk of diabetes, need to be answered. 
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Table 2.3. Summary of human studies of bisphenol A on risk of diabetes.        
F, female; M, male. 




Risk of diabetes Other comments Ref. 
Description Gender 
Cross-section USA F + M ↑  [115] 
Cross-section China F + M ×  [124] 
Cross-section USA F + M ↑  [116] 
Cross-section USA F + M ↑   [119] 
Cross-section China F + M ↑  [120] 
Cross-section Korea F + M ×  [121] 
Prospective USA F ↑  [125] 
Case-control USA F + M × During pregnancy [123] 
Cross-section USA F + M ↑  [117] 
Cross-section USA F + M ↑ Stronger link in M [118] 
Prospective USA, nurses F ↑   [126] 
Cross-section Thai F + M ↑  [127] 
Cross-section Italy F + M ↑  [128] 
Prospective Canada F ×  [122] 
Prospective China F + M ↑  [129] 
Cross-section Canada F + M ↑ only in M  [130] 
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2.6 Phthalates and diabetes 
 Phthalates were positively associated with diabetes in many studies and are summarized 
in Table 2.4. Several cross-sectional studies in the USA reported positive association between 
phthalates exposure and increased risk of diabetes [126, 131-138], while two studies reported no 
association of phthalates with risk of diabetes [122, 139]. It was suggested that diethylhexyl 
phthalates (DEHP) caused diabetes is related to oxidative stress [140]. Another study suggested 
that Mexican Americans and non-Hispanic Blacks might be more susceptible to phthalates 
induced disturbances in glucose homeostasis than non-Hispanic Whites [136]. HSP70-hom gene 
polymorphisms was also reported to contribute to the association of DEHP with insulin resistance 
[137]. However, another study observed negative association between urinary phthalate 
concentrations and blood glucose level [139]. Overall the human study about phthalates and 
diabetes is still very limited and more studies are needed before any conclusion can be made. 
2.7 Conclusion 
 Accumulating evidence are supporting the positive role of environmental pollutants in 
risk of diabetes, including some organochlorine, organophosphorous pesticides, HCB, PCB with 
less studies on carbamates, pyrethroids and neonicotinoids. However, there is still relatively small 
number of prospective studies, thus making it difficult to make firm conclusions. Questions 
including dose-response relationship and the mechanisms how the glucose metabolism is 
impaired by environmental pollutants still need to be answered. Thus, more prospective human 
studies are needed to confirm the results. It is also important to investigate the effects and the 
underlying mechanisms of these environmental pollutants on alteration of glucose and lipid 
metabolism in vitro and in vivo. 
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Table 2.4. Summary of human studies of phthalate on risk of diabetes.        
F, female; M, male. 
↑, increase; ×, no association. 
  
Study design 
Subject Risk of 
diabetes  
Other comments Ref. 
Description Gender 
Phthalate      
Cross-section USA  M ↑  ↑ Obesity [131] 
Cross-section USA 
Lactating women 
F ↑  [132] 
Cross-section USA, elderly F + M ↑  [133] 
Cross-section USA  F ↑  [134] 
Cross-section USA, adolescents F + M ↑  [135] 
Cross-section Korea F + M ↑ ↑ Oxidative stress [140] 









Prospective USA, nurses F ↑   [126] 
Cross-section Belgium, obese  F + M ↑  [138] 
Cross-section USA, pregnant F × ↑ Glucose [139] 
Di-isononyl phthalate (DINP) & di-isodecyl phthalate (DIDP)  
Cross-section USA, adolescents F + M ↑  [141] 




FIPRONIL PROMOTES ADIPOGENESIS VIA AMPKα-MEDIATED PATHWAY IN 
3T3-L1 ADIPOCYTES 
3.1 Introduction 
Fipronil (5-amino-1-[2, 6-dichloro-4-(trifluoromethyl) phenyl]-4-[(trifluoromethyl) 
sulfinyl]-1H-pyrazole-3-carbonitrile) is one of the important broad spectrum insecticides used for 
the control of arthropod pests, which threaten agricultural yields and the health of humans and 
other animal species [142].  As a phenylpyrazole compound, fipronil’s action is attributable to the 
potent, antagonistic action at the neurotransmitter gamma-aminobutyric acid (GABA) receptor. In 
addition, fipronil disrupts the insect nervous system by blocking both GABA-gated chloride and 
glutamate-gated chloride (GluCl) channels [143]. Given that fipronil has a higher binding affinity 
to insect GABA receptors, and mammals do not have glutamate-gated chloride channels, fipronil 
has a selective toxicity towards insects compared to mammals [144, 145].  
Fipronil is known to be degraded in the environment through photolysis, oxidation, and 
reduction. It is reported that fipronil is more susceptible to photolysis (half life, ~8 hr) than 
hydrolysis (half life, > 100 days) in water at pH 5 [146]. Interestingly, desulfinyl fipronil, a 
primary photolysis product of fipronil, has approximately 10-fold higher affinity for mammalian 
GABA receptors than the parent fipronil and substantially reduces selectivity between insects and 
mammals [145]. As fipronil has been formulated into a variety of products, such as solid insect 
baits, liquid sprays, and a granular products, it has been used to control a broad range of 
arthropod pests, including the boll weevil, grasshoppers, plant hoppers, ants, cockroaches, 
termites, fleas and ticks [147]. This wide range of usage makes animal and human exposure to 
fipronil nearly unavoidable [148]. Pesticides ingestion are potential risks for metabolic disorders, 
and fipronil is listed as risk level 3, which needs to be particularly monitored in food [149]. Based 
 26 
on previous publications on the relationships between exposure to insecticides and obesity, 
including our previous reports of other types of insecticides promoting adipogenesis in 3T3-L1 
adipocytes [4-7, 150-153], we presently determine the role of fipronil in adipogenesis using the 
3T3-L1 adipocyte model. 
3.2 Materials and Methods 
3.2.1 Materials 
 3T3-L1 preadipocytes were obtained from American Type Culture Collection (Manassas, 
VA). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), 
methylisobutylxanthin, insulin, dexamethasone, dimethyl sulfoxide (DMSO), 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR), and fipronil were purchased from Sigma-Aldrich Co. 
(St. Louis, MO). The contents of triglyceride and protein were quantified using kits from Thermo 
Scientifics (Middletown, VA) and Bio-Rad Co. (Hercules, CA), respectively. Trizol was bought 
from Thermo Scientific (Rockford, IL) and other chemicals were purchased from Fisher 
Scientific (Pittsburgh, PA). Radioimmunoprecipitation assay (RIPA) buffer supplemented with 
1% protease inhibitor was purchased from Boston Bioproducts Inc. (Ashland, MA).   
3.2.2 3T3-L1 Culture 
3T3-L1 preadipocytes were cultured as described in a previous paper [7]. 3T3-L1 
preadipocytes were maintained in DMEM with 10% FBS at 37 °C until confluence. 2 days after 
confluence (day 0), adipocyte differentiation was induced with DMEM containing 10% FBS and 
a mixture of methylisobutylxanthin (0.5 mM), dexamethasone (1 μM), and insulin (1 μg/mL). On 
day 2, the medium was changed to DMEM containing 10% FBS and insulin only. From day 4, 
cells were maintained in DMEM plus 10% FBS, and the medium was changed at 2-day intervals. 
Cells were treated with fipronil (0.1, 1, and 10 µM) or 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) (40 µM) from day 0 as indicated in each figure legend. Fipronil (100 
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mM) and AICAR (0.4 M) stock solutions were prepared in DMSO. Control was treated with 
DMSO and all treatments had DMSO at a final concentration of 0.02%. We didn’t observe any 
influences of these concentrations of fipronil on cell viability measured by a 3-(4,5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) based assay method as previously 
described [154] (data not shown).   
3.2.3 Triglyceride quantification 
Cells were washed with phosphate-buffered saline (PBS) and harvested by scraping in 
PBS containing 1% Triton-X after 8 days of differentiation. Homogenous samples were obtained 
from cells by sonication. The amount of triglyceride (TG) in the samples was measured with a 
commercial assay kit (Infinity™ Triglycerides Reagent; Thermo Scientific) and the protein 
content was measured with Bio-Rad DC protein assay kit according to manufacturer’s 
instructions. TG content was normalized with protein concentration.  
3.2.4 mRNA expression analysis 
Trizol reagent was used to extract total RNA from cells under RNase free conditions. 
Total RNA was reverse-transcribed with Moloney murine leukemia virus (M-MLV) reverse 
transcriptase (high-capacity reverse transcription kit, Applied Biosystems). mRNA expression 
levels of CCAAT/enhancer-binding protein α (C/EBPα), peroxisome proliferator-activated 
receptor gamma (PPAR-γ), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), fatty acid 
binding protein 4 (FABP4), adipose triglyceride lipase (ATGL), glucose transporter 4 (GLUT4), 
and leptin were analyzed from 3T3-L1 adipocytes. Real-time polymerase chain reaction (PCR) 
was performed on a StepOne Plus real time PCR instrument (Applied Biosystems, Carlsbad, CA) 
and Taqman probe-based gene expression analysis (Applied Biosystems, Carlsbad, CA). 
Respective integrated sequences for Taqman gene expression were NM_007678.3 (C/EBPα), 
NM_001127330.2 (PPAR-γ), NM_133360.2, NM_007988.3 (FAS), NM_024406.2 (FABP4), 
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NM_001163689 (ATGL), NM_009204.2 (GLUT4), and NM_008493.3 (leptin), with 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_008084.2) as an internal standard. 
3.2.5 Immunoblotting 
Cells were lysed with RIPA buffer supplemented with phosphatase inhibitor cocktail and 
protease inhibitor cocktail (Thermo Scientific, Rockford, IL). Protein concentrations were 
determined using the protein DC assay kit (Bio-Rad Co., Hercules, CA). Cell lysates containing 
50 μg of protein were separated with 6% or 10 % SDS-polyacrylamide gel and transferred to 
Immobilin P membrane (Millipore, Bedford, MA). Primary rabbit antibodies were diluted 
following the recommendation of producers. β-actin was used as an internal control. Horseradish 
peroxidase conjugated goat anti-rabbit IgG was used as the secondary antibody. Detections were 
performed on an image Station 4000MM (Carestream Health, New Haven, CT) with ClarityTM 
Western ECL Substrate Kit (Bio-Rad Co., Hercules, CA). Image and results were quantified with 
Image J software [155]. 
3.2.6 Statistical analyses 
Data were analyzed by the analysis of variance procedure (ANOVA) using the Statistical 
Analysis System (SAS Institute, Cary, NC). Tukey’s multiple-range test was used to determine 
significant differences between treatments. Significance of differences was defined at the P<0.05 
level. 
3.3 Results 
3.3.1 Triglyceride measurements in 3T3-L1 adipocytes    
Fig. 3.1 shows effects of fipronil on lipid accumulation in 3T3-L1 adipocytes. Fipronil 
(10 M) treatment significantly increased TG content, compared to control, but not at lower 
concentrations, in this model.   
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3.3.2 Influence of fipronil on genes controlling adipocyte differentiation and lipid  
metabolism 
Treatment with fipronil (10 M) significantly increased expression of two key genes 
involved in adipocyte differentiation, CCAAT/enhancer-binding protein α (C/EBPα) and 
peroxisome-proliferator activated receptor-γ (PPARγ), compared to control (Fig. 3.2A and 3.2B). 
Fipronil (10 M) also significantly increased expression of two rate limiting enzymes for 
lipogenesis, fatty acid synthase (FAS) and acetyl Co-A carboxylase (ACC) (Fig. 3.2C and 3.2D), 
compared to control. Expression of fatty acid-binding protein 4 (FABP4), a protein transporting 
fatty acids in cytoplasm for metabolic process or storage [156] was likewise increased 
significantly by 10 M fipronil treatment compared to control (Fig. 3.2E). These results show that 
fipronil promoted adipocyte differentiation and lipogenesis, contributing to increased lipid 
accumulation at 10 M.  
Expression of glucose transporter 4 (GLUT4), a 12 transmembrane protein that plays a 
major role in insulin mediated glucose transport in adipocytes [157], was also significantly 
increased following 10 M fipronil treatment compared to control (Fig. 3.2F). This finding 
suggests that fipronil may have altered glucose metabolism, which also contributes to increased 
lipid accumulation in this model. Fipronil treatment, up to 10 M, did not affect expression of 
leptin and adipose triglyceride lipase (ATGL) (Fig. 3.2G and 3.2H), which are known to correlate 
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Figure 3.1. Fipronil treatment increased triglyceride accumulation in 3T3-L1 adipocytes. Cells 
were treated with fipronil for 8 days. Each value is expressed as the mean ± standard error of 3 
independent experiments (n=10-12). Means with different letters were significantly different at 
P<0.05. 
3.3.3 Effects of fipronil on the protein expression of regulators controlling adipogenesis 
We further investigated the influence of fipronil on the protein expression of key 
regulators of adipogenesis (Fig. 3.3). Compared to control, fipronil (10 M) treatment 
significantly increased the protein expression of C/EBPα and PPAR (Fig. 3.3B and 3.3C). 
AMPKα is a master regulator of energy production and lipid metabolism in the cell [160].  
Fipronil (10 M) treatment decreased the phosphorylation of AMPKα significantly compared to 
control, without affecting the total levels of AMPKα (Fig. 3.3D, 3.3E and 3.3F). These results 
indicate reduced activation of AMPKα by fipronil. Expression of ACC (active form), a 
downstream target of AMPKα, was increased significantly, while phosphorylation of ACC 
(inactive form) was decreased significantly by fipronil treatment compared to control (Fig. 3.3G, 
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Figure 3.2. Effects of fipronil on gene expression of molecular mediators of adipogenesis. 
C/EBP-α, CAATT element binding protein-α; PPARϒ, Peroxisome proliferator-activated 
receptor gamma; FAS, Fatty acid synthase; ACC, Acetyl-CoA carboxylase; FABP4, Fatty acid 
binding protein 4; GLUT4, Glucose transporter type 4; HSL, Hormone-sensitive lipase; LPL, 
Lipoprotein lipase; ATGL, Adipose triglyceride lipase. Numbers represent mean ± S.E. (n=4-6).  





Figure 3.3. Effects of fipronil on protein levels of molecular mediators of adipogenesis. C/EBP-α, 
CAATT element binding protein-α; PPAR-γ, peroxisome proliferator-activated receptor-γ; 
AMPKα , AMP-activated protein kinase-α (inactive form); pAMPKα, phosphorylated AMPKα 
(active form), ACC, acetyl-CoA carboxylase (active form); pACC, phosphorylated ACC (inactive 
form). Cells were treated with fipronil for 8 days. Numbers represent mean ± S.E. (n=3). Means 
with different letters were significantly different at P<0.05. 
3.3.4 Effect of AMPKα activation on adipogenesis induced by fipronil 
 We next investigated whether AMPKα activation could inhibit enhanced adipogenesis 
induced by fipronil. An AMPK activator, 5-amino-4-imidazolecarboxamide riboside-1-β-D-
ribofuranoside (AICAR) is an adenosine analogue, which is taken up by adenosine transporters 
on the cell membrane and then is phosphorylated to generate 5-amino-4-imidazolecarboxamide 
ribotide (ZMP). ZMP mimics AMP and stimulates AMPK phosphorylation in the cell [161]. As 
shown in Fig. 4.4, AICAR treatment alone decreased fat accumulation, while 10 M fipronil 
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treatment alone increased fat accumulation. When cells were treated with AICAR and fipronil 


















































Figure 3.4. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased 
fat accumulation induced by fipronil. Cells were treated with fipronil (10 µM) or AICAR (40 
µM) for 8 days. Numbers represent mean ± S.E. (n=3). Means with different letters were 
significantly different at P<0.05. 
3.3.5 Influence of AMPKα activation on protein expression of regulators controlling 
adipogenesis 
As expected (Fig. 3.5), AICAR treatment alone significantly decreased the expression of 
C/EBPα, ACC, while expressions of pAMPKα and pACC were significantly increased compared 
to controls. When cells were treated together with fipronil and AICAR, increased protein 
expression of C/EBPα, ACC and decreased expression of pAMPKα and pACC induced by 
fipronil were abolished by AICAR treatment.  These results suggest that AMPKα activation could 
abolish enhanced adipogenesis induced by fipronil. 
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Figure 3.5. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased 
expression of C/EBPα, ACC and the decreased expression of PAMPKα, PACC induced by 
fipronil. C/EBP-α, CAATT element binding protein-α; ACC, acetyl-CoA carboxylase (active 
form); pAMPKα, phosphorylated AMPKα (active form); pACC, phosphorylated ACC.  Cells 
were treated with fipronil (10 µM) or AICAR (40 µM) for 8 days. Numbers represent mean ± 
S.E. (n=3-4). Means with different letters were significantly different at P<0.05. 
3.4 Discussion 
 Results from the current study suggest that fipronil exposure contributes to increased 
adipogenesis in 3T3-L1 cell model. To our knowledge, this is the first report linking enhanced 
adipogenesis to fipronil, particularly at 10 M. We further expand our understanding that 
AMPKα pathway is involved in increased adipogenesis induced by fipronil.  
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 AMPK is the downstream component of a protein kinase cascade that has a central role in 
the regulation of energy balance and lipid metabolism [162].  Activation of AMPK has been 
suggested to inhibit adipogenesis with reduced expression of PPAR, C/EBPα and late 
adipogenic markers such as FAS and ACC [163]. Activation of AMPK has also been reported to 
inhibit lipogenesis by phosphorylation of ACC, the key regulated step in fatty acid synthesis and 
fatty acid oxidation. ACC catalyzes the synthesis of malonyl-CoA, a substrate of fatty acid 
synthesis, and is inhibited by AMPK-mediated phosphorylation of ACC [164]. In the current 
study, the concentration of AICAR used is 40 µM, which is lower than a previous report [163]. 
We tested the effects of different AICAR concentrations (40, 150 and 500 µM) on 3T3-L1 
viability as well as adipogenesis. We found that all three doses can inhibit adipogenesis 
effectively in our cell culture model. However, AICAR concentrations (150 and 500 µM) 
decreased cell viability. Thus we chose AICAR (40 µM) in the following study. Our current 
results suggest that fipronil may influence lipid metabolism via post-translational regulation of 
AMPK. With the current results, it is not clear if fipronil directly or indirectly targets AMPK. 
However, fipronil has previously been reported to increase intracellular Ca2+ levels, by alteration 
of the permeabilization of plasma membrane induced by fipronil [165].  Based on reports that 
chronic elevation of intracellular calcium might impair the activation of AMPK, via 
calcium/calmodulin kinase kinase-β (CaMKKβ) [166, 167],  it is possible that fipronil may 
influence intracellular calcium levels and lead to altered adipogenesis and lipid metabolism via 
CaMKKβ-and AMPK- mediated mechanisms. However, fipronil’s effect on intracellular calcium 
needs to be further confirmed in the future. 
  In the current study, no significant differences of leptin mRNA were found between 
control and fipronil treatment groups in this model. Although we did not measure leptin secretion 
in this study, it is known that expression of leptin is well correlated to leptin secretion in the 3T3-
L1 model. Previously, Lassiter and Brimijoin [150] reported that organophosphorus insecticide 
treatment could impair leptin production. Two previous publications from our group consistently 
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reported that imidacloprid and permethrin had no effect on leptin expression, which suggests 
impaired leptin production by these insecticides [3, 6, 7]. Thus, the lack of effects of fipronil on 
leptin expression might be due to impaired leptin signaling by fipronil treatment. This may also 
contribute to altered lipid accumulation, as leptin plays an important role in regulating food intake 
and glucose metabolism [168].     
The toxicity symptoms of fipronil in mice include hyperactivity, irritability, convulsions, 
leading to death [169, 170], with the oral LD50 of fipronil in rat being 97 mg/kg body weight 
[169, 170].  Fipronil might potentially be a metabolic disorder, due to its ability to induce hepatic 
phase I CYP enzymes, which have great potential to interact with other xenobiotics or 
endogenous chemicals, which are substrates of the CYP1A, CYP2B and CYP3A subfamilies 
[171]. The ADI (acceptable daily intake) of fipronil was determined to be 0.0002 mg/kg body 
weight, based on the oral NOAEL (no observed adverse effect level) of 0.019 mg/kg body 
weight/day in a 2-year study of toxicity and carcinogenicity in rats [169, 170]. The major 
metabolite of fipronil detected in adipose tissue, liver, kidney, and muscle of rat was the fipronil 
sulfone, while two main metabolites, fipronil sulfone and fipronil amide, were found in urine 
[169, 170].  In a pharmacokinetics study of fipronil in rats using 14C-fipronil administered orally 
at a single dose of 4 mg/kg body weight, the radioactivity in blood reached a maximum value 5.5 
hours after treatment and decreased thereafter, with an elimination half-life of 183 hours. The 
relative long half-life  suggests the bioaccumulation of metabolic products from fipronil may 
have occurred in adipose tissue [170]. In fact, the highest concentration of fipronil sulfone in 
adipose tissue reported was 31 ppm, which is equivalent to ~70 μM [169, 170].   
Currently, only limited information exists concerning the serum levels of fipronil in 
humans. One occupational exposure study of workers at a fipronil production facility reported 
fipronil sulfone serum level of 17.8 nM, although the levels of fipronil or its metabolites in 
adipose tissue levels were not measured [172]. The plasma levels of total fipronil (including its 
metabolites) in patients who were orally exposed to fipronil ranged from 0.12 to 9.15 μM [173]. 
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Thus, levels of fipronil used in the present study were higher than potential exposure levels for 
most populations.  Nevertheless, based on observation that fipronil and its metabolites 
bioaccumulate in adipose tissue (~70 μM) [169, 170], the findings of the current study may have 
significant implication for the role of fipronil on adipogenesis. 
In comparison to the biological fate of fipronil above, it is also known to be degraded in 
the environment through photolysis, oxidation, and reduction [146]. Fipronil is particularly 
sensitive to photolysis with half-life of ~8 hr, resulting in desulfinyl fipronil as the primary 
photolysis product [145]. This metabolite has a 10-fold higher affinity for mammalian GABA 
receptors than parent fipronil and reduces selectivity substantially between insects and mammals 
[145]. Thus, it is also important to determine the potential role of metabolites of fipronil from 
both biological and environmental systems.  
To summarize, our present finding reports the influence of fipronil on enhanced 
adipocyte differentiation and increased fat accumulation in adipocytes and are significant in 
providing a potential link between insecticide exposure, particularly fipronil, and impaired 
adipocyte functions. Nonetheless, our current results are limited to an in vitro model using 
relatively high doses of fipronil. In addition, the role of fipronil metabolites still needs to be 
determined. Thus, further in vivo studies of fipronil, as well as epidemiological studies, are 






IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY AND 
INSULIN RESISTANCE IN MALE C57BL/6J MICE 
 
4.1 Introduction 
 Since its introduction to the market in 1991, imidacloprid  
(N-{1-[(6-Chloro-3-pyridyl)methyl]-4,5-dihydroimidazol-2-yl}nitramide) is the most successful 
neonicotinoid insecticide containing the 2-(N-nitroimidazolidin) pharmacophore and the (6-
chloropyrid-3-yl) methyl  residue [174]. Imidacloprid has been widely used on various types of 
grains, vegetables, fruits, and turf to control agricultural insect pests as well as on domesticated 
animals to control ectoparasitic arthropods (e.g. K9 Advantix II and Advatage) [175-177]. In 
2009, the market sales for imidacloprid in the US alone was estimated to be 1.1 billion USD 
[175]. This extensive use of imidacloprid in agriculture, including seed dressing, in recent years 
might further add to its soil [178, 179] and water [180]  as well as detection in various kinds of 
fresh and processed fruits and vegetables [39]. These suggest that the potential for human 
exposure to imidacloprid, in the general public as well as agricultural workers, would be 
relatively high. Imidacloprid use was restricted by the European Commission in 2013 along with 
two other neonicotinoids due to its potential risk for the collapse of bee populations [43]. The 
selective potency of imidacloprid to insects versus mammals has been well characterized and 
attributed to the higher affinity at the insect nicotinic acetylcholine receptors (nAChRs) [40, 181-
184]. This selective action of imidacloprid and its systemic property make imidacloprid a 
preferable choice of insecticide in various field situations [175]. In addition, imidacloprid is 
relatively more water soluble when compared to other classes of insecticides (e.g., 
organochlorine, organophosphorus and pyrethroid insecticides) and penetrates human skin 
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slowly. Imidacloprid is also known to be quite persistent with approximately a 39 days of 
photolysis half-life at the soil surface (a range of 26.5-229 days) and an aerobic half-life of ~3 
years [185]. Moreover, it is known that a plant metabolite, desnitro imidacloprid, has been 
determined to be more toxic to mammals than the parent compound [186, 187].  
  Epidemiological studies suggest a link between exposure to persistent organic pollutants, 
including insecticides, and the epidemic of obesity and diabetes[60, 91, 188-190]. Recently, one 
animal study reported that exposure to contaminated salmon oil containing persistent organic 
pollutants along with a high fat diet resulted in insulin resistance, represented by 
hyperinsulinemia, glucose intolerance, and hypertriglyceridemia, as well as hepatic steatosis, 
compared to control fed high fat diet alone in rats [191]. Another study reported that exposure to 
dichlorodiphenyldichloroethylene (DDE) has a biphasic effect on fasting blood glucose in high 
fat diet fed male mice [192]. Previously, a single study reported that 20 mg imidacloprid/kg body 
weight/day through oral gavage decreased body weight accompanied with significant elevation of 
serum glucose, glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT) 
and blood urea nitrogen in rats, while 10 mg imidacloprid /kg body weight /day did not show 
such toxic effect [193]. Another study concluded that imidacloprid (5 and 10 mg/kg bw/day) has 
immunosuppressive effects, which might result from the direct cytotoxic effects of imidacloprid 
against T-cells [177]. Moreover, there are recent reports that imidacloprid may have adverse 
effects on development [194, 195]. Along with these reports, our previous published studies 
reported that several pesticides, including imidacloprid, promotes adipogenesis in 3T3-L1 
adipocytes and induces insulin resistance in C2C12 myotubes [6, 9, 196-198]. It is not known, 
however, if imidacloprid exposure alone or in combination with other factors of obesity and 
insulin resistance, such as high fat diet, will exacerbate obesity and insulin resistance symptoms. 
Thus, the current study was conducted to determine if exposure to imidacloprid aggravated high 
fat diet-induced metabolic disorders characterized by adiposity, dyslipidemia, hyperglycemia, and 
insulin resistance in male C57BL/6J mice. 
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4.2 Materials and Methods 
4.2.1 Materials 
 Imidacloprid (>98%) was purchased from Chem Service Inc. (West Chester, PA, USA). 
Three-week-old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA). Semi-purified powdered diets (TD 94048, 4% fat w/w, low fat diet and TD 07518, 
20% fat w/w, high fat diet) were based on Harlan Laboratories (Madison, WI, USA) diets. Food 
ingredients were obtained from Bio-Serv (Flemington, NJ, USA). Glucose and total cholesterol 
assay kits were purchased from Genzyme Diagnostics (Charlottetown, PE, Canada). Mouse leptin 
assay kit was purchased from R & D Systems (Minneapolis, MN, USA). Non-esterified fatty acid 
assay kit was from Wako Life Sciences, Inc. (Mountain view, CA, USA). Serum insulin level was 
analyzed with Mouse insulin ELISA kit from ALPCO (Salem, NH, USA). The amounts of 
triglyceride were quantified using Infinity™ Triglycerides Reagent from Thermo Scientific 
(Waltham, MA, USA), and other chemicals were purchased from Fisher Scientific (Pittsburgh, 
PA, USA). Radioimmunoprecipitation assay (RIPA) buffer supplemented with 1% protease 
inhibitor was purchased from Boston Bioproducts Inc. (Ashland, MA, USA). Rabbit antibodies to 
AMPKα, phosphorylated AMPKα (pAMPKα), acetyl-CoA carboxylase (ACC), phosphorylated 
ACC (pACC) and horseradish peroxidase-conjugated goat anti-rabbit IgG were purchased from 
Cell Signaling Technology (Beverly, MA, USA). Rabbit antibodies to Sirtuin 1 (SIRT1), 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and β-actin 
were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). Ca2+/calmodulin-
dependent protein kinase kinase β (CAMKKβ) rabbit antibody was purchased Abcam Inc. 
(Cambridge, MA, USA). Human recombinant insulin (Novolin, 100 U/ml) was purchased from 
Novo Nordisk Pharmaceuticals Industries Inc. (Seattle, WA, USA). Dextrose (50%) and 
bacteriostatic 0.9% sodium chloride injection were obtained from Hospira, Inc. (Lake Forest, IL, 
USA). 
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4.2.2 Animals and diet 
All animal work was conducted in compliance with the Institutional Animal Care and 
Use Committee at the University of Massachusetts under protocol number 2013-0014. Mice were 
housed in a temperature and humidity-controlled room with a 12-h light/dark cycle. The 
compositions of diets are shown in Table 1. Diet and water were given to mice ad libitum 
throughout the experiment and were provided fresh twice a week. Body weight and food intake 
were monitored weekly. After 2-week adaptation, the mice were fed a control diet (4% fat w/w) 
and subjected to baseline tests for insulin tolerance and glucose tolerance. All animals were then 
divided to two dietary groups (low fat and high fat diet), each dietary treatment group contained 
four imidacloprid treatment doses (0, 0.06, 0.6 and 6 mg/kg bw/day). The treatment lasted for 12 
weeks. Doses of imidacloprid were determined based on previous publications; the highest 
imidacloprid dose was based on no-observed-adverse-effect-level (NOAEL) of imidacloprid at 
5.7 mg/kg bw/day and the lowest dose of imidacloprid was based on estimated average daily 
intake of imidacloprid of 60 µg/kg body weight/day [199-201].  Imidacloprid content in low fat 
diets were 0, 0.516, 5.16 and 51.6 mg imidacloprid/kg diet. Imidacloprid content in high fat diets 
were 0, 0.744, 7.44 and 74.4 mg imidacloprid/kg diet. The average consumption of imidacloprid 
at the end of the study was 0, 0.07, 0.7 and 7 mg/kg bw/day in low fat dietary groups and 0, 0.08, 
0.8 and 7 mg/kg bw/day in high fat dietary groups. Imidacloprid intake between low fat diet and 
high fat diet was not statistically different. 
 At the end of the study, mice were fasted for 4 h and sacrificed by CO2 asphyxiation. 
Blood was collected by cardiac puncture, and serum was separated by centrifugation at 2000 g for 
20 min. The organs (kidney, heart, liver, spleen, pancreas and adipose tissues including 
epididymal, mesenteric, retroperitoneal, and subcutaneous adipose tissues) were weighed 
following sacrifice. One-eighth of the epididymal adipose tissue were kept in 10% buffered 
formalin and used for adipocyte size determination. The other parts of the epididymal adipose 
tissue and all other organs including gastrocnemius and quadriceps were snap frozen with liquid 
 42 
nitrogen and stored at -80 C until analysis. 
 Table 4.1. Composition of diet   
Ingredient 
Low fat diet 
Amount (g/kg)   
High fat diet 
Amount (g/kg) 
Casein 140 169.1 
L-Cystine 1.8 2.2 
Sucrose 100 100 
Cornstarch 465.692 288.5 
Maltodextrin 155 132 
Cellulose 50 50 
Soybean oil 40 200 
Mineral mix, AIN-93M-MX (TD 94049) 35 42.8 
Vitamin mix, AIN-93-VX (TD 94047) 10 12.4 
Choline bitartrate 2.5 3 
tert-Butylhydroquinone 0.008 0.04 
Total 1000 1000 
4.2.3 Serum parameters 
 The levels of total cholesterol, leptin, non-esterified fatty acids (NEFA), triglyceride (TG) 
and insulin in serum were determined with commercial kits following the manufacturers’ 
instructions. 
4.2.4 Insulin tolerance test 
Insulin tolerance test (ITT) was performed during adaptation and treatment at week 5 and 
week 9 as previously described [202]. All mice were fasted for 4 h. Blood glucose from the tail 
vein was measured at 0, 15, 30, 60 and 120 min post intraperitoneal injection of insulin solution 
(0.75 U/kg body weight), with a blood glucose meter, Advocate Redi-Code+ (Advocate Meters 
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Inc., Dorado, Puerto Rico). The areas under the curve (AUC) were calculated with Sigma Plot 
11.0 (Systat Software, Inc., San Jose, CA, USA). 
4.2.5 Glucose tolerance test 
 Glucose tolerance tests (GTT) were performed during adaptation and treatment at week 6 
and week 11 as described previously [202]. All mice were fasted for 6 h before the first 
measurement of blood glucose from the tail vein and blood glucose was measured with a blood 
glucose meter (0 min). Then, 20% glucose solution (2 g glucose/kg of body weight) was 
administered intraperitoneally and blood glucose levels were further monitored at 15, 30, 60, and 
120 min. Blood insulin level was also measured at 0, 30, 60 and 120 min with mouse insulin 
ELISA kit from ALPCO (Salem, NH, USA). AUC were calculated with Sigma Plot. The 
homeostasis model assessment- insulin resistance (HOMA-IR) score was calculated with HOMA-
IR calculator (University of Oxford) [203].  
4.2.6 Adipocyte size measurement 
 Epididymal adipose tissue was fixed in 10% phosphate-buffered formalin and processed 
for paraffin sectioning [204]. Tissue sections (4 µm) were cut and stained with hematoxylin and 
eosin (HE) staining. Pictures were taken with Olympus CK2 inverted microscope (Olympus, 
Tokyo, Japan) (100 x magnification) and microscope eyepiece camera (AmScope, Irvine, CA). 
Adipocyte size was measured as previously described with Image J software with minor 
modification [205]. Mean area of 50 cells from each sample were measured with Image J 
software. Briefly, the pictures of calibration slide (AmScope, Irvine, CA) were taken under the 
same settings as the tissue sections and were used to set the scale in image J, then the area of the 
adipocytes were measured with Image J. 
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4.2.7 mRNA expression analysis 
 Mouse epididymal adipose tissue, liver, and gastrocnemius muscle were homogenized in 
Trizol reagent to extract total RNA under RNase free conditions. Total RNA was reverse-
transcribed with high-capacity reverse transcription kit (Applied Biosystems, Carlsbad, CA). 
mRNA expression levels of fatty acid translocase (FAT/CD36), sterol regulatory element-binding 
protein 1c (SREBP1c), tumor necrosis factor α (TNF-α), phosphoenolpyruvate carboxykinase 
(PEPCK), peroxisome proliferator-activated receptor alpha (PPARα), glucose transporter type 4 
(GLUT4), pyruvate dehydrogenase kinase 4 (PDK4), carnitine palmitoyltransferase 1B (CPT1b), 
and 18S ribosomal RNA (18S rRNA) were analyzed. Real-time polymerase chain reaction (PCR) 
was completed using a StepOne Plus real time PCR instrument (Applied Biosystems, Carlsbad, 
CA, USA) and Taqman probe-based gene expression analysis (Applied Biosystems, Carlsbad, 
CA, USA). Respective integrated sequences used were NM_001159555.1 (CD36), NM_011480.3 
(SREBP1c), NM_001278601.1 (TNFα), NM_028994.2 (PEPCK), NM_001113418.1 (PPARα), 
NM_009204.2 (GLUT4), NM_013743.2 (PDK4), NM_009948.2 (CPT1b), and NR_003278.3 
(18S rRNA). 
4.2.8 Immunoblotting 
 Mouse tissues were prepared for immunoblotting as previously described [198]. Protein 
quantities were determined using the assay kit (Bio-Rad Co., Hercules, CA). β-actin was used as 
an internal control. The secondary antibody was goat anti-rabbit IgG conjugated with horseradish 
peroxidase. Detections were performed on an image Station 4000MM (Carestream Health, New 
Haven, CT) with ClarityTM Western ECL Substrate Kit (Bio-Rad Co., Hercules, CA, USA). 
Images were quantified with Image J software [155]. 
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4.2.9 Statistical analyses 
 Data were analyzed by PROC MIXED of the SAS software (Version 9.3, SAS Institute 
Inc., Cary, NC, USA). For the result on body weight (Figure 1A), two-way repeated measure 
Analysis of Variance (ANOVA) and the slice option in the Least Square (LS) means statement 
were used to determine the differences at each time point. For all the other results, two-way 
ANOVA along with LS means statement was used. The Tukey-Kramer’s method was applied for 
the multiple comparisons among the groups. P-values less than 0.05 are reported as statistically 
significant. If there were significant interactions between diet and imidacloprid, letters were used 
in the figures to present the differences between each group. When there were no interactions 
between diet and imidacloprid, brackets were used in the figures to represent overall differences 
between imidacloprid treatments and control groups. 
4.3 Results 
4.3.1 Imidacloprid promoted weight gain in high fat diet fed mice 
 To understand the effect of imidacloprid on dietary fat induced changes, we chose 
C57BL/6J male mice fed with either low fat (4%) or high fat (20%) diet. High fat diets (~40-70% 
of kcal) are known to induce obesity in this strain[206]. There were overall effects of diet or 
imidacloprid on body weight (Fig. 4.1A). Significant 3-way interaction (imidacloprid x diet x 
time) was also observed. In high fat diet fed mice, all imidacloprid groups showed significant 
increase in body weight compared to the control group from week-7 onward and maintain the 
trend throughout the experiment (p<0.001 for all weeks from 7 to 12) (Fig. 4.1A). No differences 
of body weight were found in the low fat diet fed mice among all groups throughout the 
experiment (Fig. 4.1A). Overall, both dietary fat and imidacloprid significantly affected body 
weight gain and there was a significant interaction between dietary fat and imidacloprid (Fig. 
4.1B). In high fat diet fed mice, imidacloprid treatment groups (0.06, 0.6 and 6 mg/kg bw/day) 
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had significantly greater weight gain compared to the high fat control group (p=0.0057, 0.0149 
and 0.0038, respectively) (Fig. 4.1B). 
 Food intake as determined by calorie consumption is shown in Fig. 4.1C.  Both 
imidacloprid and dietary fat significantly affected the calorie intake alone but without any 
interaction between them (Fig. 4.1C). Mice fed with high fat diet had more calorie intake 
compared to mice fed with low fat diet (p=0.0080). There were no significant differences of 
calorie intake between control and three imidacloprid treatment groups. However, there was 
significant difference of calorie intake between 0.06 and 6 mg/kg bw/day imidacloprid treatment 















Figure 4.1. Effects of imidacloprid on body weight, body weight gain and food intake. Mice were 
fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) 
imidacloprid for 12 weeks. (A) Body weight was monitored weekly, (B) Body weight gain for 12 
weeks. (C) Total food intake. Numbers are mean ± S.E. (n=5-8 for A & B, n=3-4 for C). Means 
with different letters were significantly different at P<0.05.  
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4.3.2 Influence of imidacloprid on tissue and organ weights 
 Organ weights (liver, pancreas, heart, kidneys, and spleen) as well as adipose tissue 
weights (epididymal, subcutaneous, mesenteric, retroperitoneal, and total adipose tissue) 
measured as % of body weights are shown in Table 4.2. There was a significant diet effect, but 
there were no imidacloprid and diet x imidacloprid interaction effects on liver, heart and spleen 
weights. Both imidacloprid and diet significantly affected the kidney weight with a significant 
interaction. In high fat diet fed mice, imidacloprid treatment groups (0.06 and 6 mg/kg bw/day) 
had reduced kidney weight compared to control group (p=0.0297 and 0.0006, respectively). 
There were overall effects of diet and imidacloprid on all adipose tissue weights with interaction, 
except for mesenteric adipose tissue, where only a diet effect was observed. In high fat diet fed 
mice, animals treated with imidacloprid (0.6 and 6 mg/kg bw/day) had significantly greater 
epididymal (p=0.0337 and 0.0002, respectively) and retroperitoneal (p=0.0078 and 0.0008, 
respectively) adipose tissue weights compared to control group.   
 Histological analysis revealed that there were significant effects of diet and imidacloprid 
with diet x imidacloprid interaction on epididymal adipocyte size (Fig. 4.2). Imidacloprid (0.06, 
0.6 and 6 mg/kg bw/day) treatment significantly increased adipocyte size in high fat diet fed mice 
(p=0.0081, 0.0002 and 0.0001, respectively), but not in low fat diet fed mice (Fig. 4.2A & 4.2B). 
 
4.3.3 Influence of imidacloprid on serum markers 
 The serum levels of glucose, cholesterol, leptin, NEFA, TG and insulin are shown in 
Table 4.3. There were overall treatment effects from both diet and imidacloprid (without 
interaction) on blood glucose and insulin levels. Mice fed with imidacloprid (0.06 and 6 mg/kg 
bw/day) had significantly higher levels of blood glucose compared to control groups (p=0.0096 
and 0.0144, respectively). Mice fed with imidacloprid (6 mg/kg bw/day) also had significantly 
higher blood insulin levels compared to control groups (p=0.0325). There were overall treatment 
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effects from both diet and imidacloprid with their interaction on leptin level. Compared to the 
high fat control group, animals fed the high fat diet with (0.06, 0.6 and 6 mg/kg bw/day) 
imidacloprid had higher blood leptin levels (p<0.0001, 0.0011 and <0.0001, respectively). There 
were overall treatment effects from imidacloprid, but not diet and their interaction, on serum TG 
levels. Mice fed with imidacloprid (6 mg/kg bw/day) had significantly higher serum TG level 
compared to control groups (p=0.0099). There were significant effects of diet, but not to 
imidacloprid nor to their interaction, on cholesterol levels. There were no significant effects of 
both diet and imidacloprid on serum NEFA levels.  
4.3.4 Effects of imidacloprid on glucose homeostasis 
 To determine the effect of imidacloprid and diet on glucose homeostasis, we measured 
serum glucose levels during ITT and GTT and measured serum insulin level during GTT, which 
were presented in Fig. 4.3. Before treatment, there were no differences between any of the groups 
for ITT, GTT and insulin level (Fig. 4.3A, 4.3D & 4.3G).  
As shown in Fig. 4.3B, there were significant diet and imidacloprid effects without 
interaction on insulin tolerance after 5-week treatment. In particular, mice that received the 
highest dose of imidacloprid (6 mg/kg bw/day) had significantly higher AUC compared to control 
groups (p=0.0018) in week 5 (Fig. 4.3B). After 9-week treatment, there were significant effects of 
diet and imidacloprid with interaction (Fig. 4.3C). High fat diet imidacloprid treated mice at 6 
mg/kg bw/day had significantly elevated AUC compared to the high fat control (p=0.0006) (Fig. 
4.3C). 
 We further performed GTT at 6 and 11-week. As shown in Fig. 5.3E, only diet was found 
to have significant effect on impaired glucose tolerance in week 6. In week 11, both diet and 
imidacloprid effects were observed without interaction (Fig. 4.3F). At the highest dose of 
imidacloprid (6 mg/kg bw/day), treated mice showed more severe glucose intolerance compared 
to control groups (p=0.0331) (Fig. 4.3F).   
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 The serum samples collected from the GTT tests were further utilized for insulin level 
measurements. There were significant diet and imidacloprid effects with interaction on serum 
insulin level both at week 6 and 11 (Fig. 4.3H & 4.3I). High fat diet with imidacloprid treated 
animals at 0.6 and 6 mg/kg bw/day had significantly higher AUC of insulin levels compared to 
high fat controls (p<.0001 for both 0.6 and 6 mg/kg bw/day at week 6, p=0.0007 and 0.0211 at 
week 11, respectively) (Fig. 4.3H & 4.3I). Similarly, there were significant diet and imidacloprid 
effects on HOMA-IR scores with significant interaction in week 6, 11 and 12 (Fig. 4.4). High fat 
diet with imidacloprid (0.6 and 6 mg/kg bw/day) treated mice had higher HOMA-IR scores 
compared with the high fat control (Fig. 4.4).
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Table 4.2. Organ Weights (% of body weight)  
 
Low fat High fat   
P-value 
 Imidacloprid doses  Imidacloprid doses 




Liver 3.90 ± 0.12 3.86 ± 0.15 3.78 ± 0.07 3.92 ± 0.16 3.51 ± 0.18 3.57 ± 0.08 3.34 ± 0.21 3.58 ± 0.17 0.002 n.s. n.s. 
Heart 0.44 ± 00.02 0.50 ± 0.05 0.48 ± 0.02 0.48 ± 0.02 0.47 ±0.03 0.41 ± 0.03 0.41 ± 0.03 0.38 ± 0.03 0.011 n.s. n.s. 
Spleen 0.26 ± 0.03 0.20 ± 0.01 0.23 ± 0.02 0.19 ± 0.02 0.30 ± 0.02 0.27 ± 0.02 0.30 ± 0.01 0.35 ± 0.05 0.0002 n.s. n.s. 
Kidney 1.06 ± 0.05ab 1.09 ± 0.05ab 1.15 ± 0.04a 1.10 ± 0.04ab 1.12 ± 0.07a 0.88 ± 0.04bc 0.96 ± 0.03abc 0.80 ± 0.05c <0.0001 0.027 0.003 
Pancreas 0.43 ± 0.04 0.45 ± 0.02 0.48 ± 0.04 0.47 ± 0.03 0.54 ± 0.05 0.38 ± 0.02 0.42 ± 0.02 0.39 ± 0.04 n.s. n.s. 0.037 
Adipose tissue            
Epididymal 2.19 ± 0.20d  2.29 ± 0.42cd 1.64 ± 0.17d 2.00 ± 0.25d 3.57 ± 0.42bc 5.0 ± 0.31ab 5.03 ± 0.27a 5.82 ± 0.40a <0.0001 0.011 0.001 
Subcutaneous 1.36 ± 0.24cd 1.43 ± 0.37cd 0.94 ± 0.14d 1.43 ± 0.30cd 2.65 ± 0.45bc 3.79 ± 0.37ab 3.59 ± 0.28a 4.91 ± 0.56a <0.0001 0.014 0.026 
Retroperitoneal 0.59 ± 0.08c 0.57 ± 0.13c 0.39 ± 0.08c 0.51 ± 0.09c 1.09 ± 0.12b 1.50 ± 0.09ab 1.64 ± 0.09a 1.75 ± 0.14a <0.0001 0.038 0.001 
Mesenteric 1.33 ± 0.10 1.61 ± 0.20 1.23 ± 0.15 1.23 ± 0.11 2.02 ± 0.23 2.60 ± 0.19 2.64 ± 0.17 2.80 ± 0.26 <0.0001 n.s. n.s. 
Total  5.47 ± 0.58bc 5.90 ± 1.10bc 4.20 ± 0.52c 5.17 ± 0.74bc 9.34 ± 1.12b 12.9 ± 0.88a 12.9 ± 0.68a 15.3 ± 1.29a <0.0001 0.001 <0.001 
Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-8). 
Means with different superscripts within the same row are significantly different at P<0.05. Abbreviations: n.s., not significant. 
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Table 4.3. Serum Parameters 
 
Low fat High fat   
P-value 
 Imidacloprid doses  Imidacloprid doses 






162.8 ± 7.9  183.1 ± 24.1 169.7 ± 4.6 169.3 ± 17.7 178.2 ± 17.9 234.7 ± 19.1 193.7 ± 18.7 229.9 ± 15.4 0.0312 0.0034 n.s. 
Insulin 
ng/mL 
0.77 ± 0.11 0.97 ± 0.25 0.81 ± 0.07 0.97 ± 0.21 2.05 ± 0.34 3.10 ± 0.33 2.51 ± 0.37 3.36 ± 0.58 <0.0001 0.0312 n.s. 
Leptin  
ng/mL 
4.9 ± 1.0b 4.2 ± 1.4b 3.4 ± 0.7b 4.4 ± 1.2b 14.4 ± 3.7b 59.6 ± 3.2a 47.9 ± 6.1a 66.4 ± 11.5a <0.0001 <0.0001 <0.0001 
TG 
mg/dL 
77.2 ± 6.3 94.2 ± 6.1 76.3 ± 12.2 91.2 ± 8.1 63.6 ± 5.1 82.4 ± 6.0 85.0 ± 2.3 94.5 ± 6.8 n.s. 0.0104 n.s. 
Cholesterol 
mg/dL 
161.5 ± 8.7 163.7 ± 18.9 117.6 ± 11.3 150.5 ± 9.5 171 ± 15 213.4 ± 21 182.6 ± 16 219.9 ± 21.9 0.0003 n.s. n.s. 
NEFA 
mEq/L 
1.3 ± 0.1 1.4 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.0 ± 0.2 1.1 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 n.s. n.s. n.s. 
Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-8). Means with different 




Figure 4.2. Effects of imidacloprid on adipocyte size. Mice were fed with low fat diet or high fat   
diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. (A) 
Representative pictures of epididymal adipose tissues after H&E staining (100 x magnification). 
(B) Adipocyte size. The mean area of 50 cells from each sample were measured with image J. 
Data were expressed as the mean ± SE (n=3). Means with different letters were significantly 





Figure 4.3. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance test 
(GTT) (D, E, F) and insulin level determination with serum from GTT (G, H, I) as the area under 
the curve (AUC). Mice were fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 
and 6 mg/kg bw/day) imidacloprid for 12 weeks. ITT was measured during adaptation period, 
week 5 and 9. GTT was measured during adaptation period, week 6 and 11. Blood was collected 
from the tail vein, and glucose levels were determined at 0 min, then the insulin (ITT) or glucose 
solution (GTT) was administered by intraperitoneal injection and glucose level were further 
measured at 15, 30, 60 and 120 min. During GTT, the blood was collected from the tail vein at 0, 
30, 60 and 120 min for determination of insulin level. Numbers represent means ± SE (n=5-8). 




Figure 4.4. Effects of imidacloprid on HOMA-IR score. Mice were fed with low fat diet or high 
fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. HOMA-
IR score was calculated during adaptation period, week 6, 11 and 12 with HOMA-IR 
calculator[203]. Numbers represent mean ± S.E. (n=5-8). Means with different letters were 
significantly different at P<0.05. 
4.3.5 Effects on mRNA levels of genes regulating lipid metabolism and AMPKα pathway in  
epididymal adipose tissue 
 Since imidacloprid and high fat diet significantly affected the lipid and glucose 
metabolism in mice, we first investigated their effects on mRNA expression levels of genes 
regulating lipid metabolism in white adipose tissue. CD36, one of the fatty acid transporter 
proteins in adipocytes, facilitates the cellular entry of lipoprotein derived fatty acids, thus 
promoting the storage of triglycerides in adipose tissue [207].  There were significant diet and 
imidacloprid effects without interaction on CD36 mRNA expression (Fig. 4.5A). Compared to 
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control groups, mice fed with imidacloprid (6 mg/kg bw/day) had significantly higher expression 
of CD36 (p=0.011) (Fig. 4.5A).  
 SREBP1c is highly expressed in adipose tissue and is a well-known master regulator of 
the lipogenic pathway [208, 209]. There was significant imidacloprid, without diet effects or 
interaction, on SREBP1c mRNA expression in the current study (Fig. 4.5B). Mice fed with 6 
mg/kg bw/day imidacloprid had a significant increase in SREBP1 expression compared to 
controls (p=0.0035) (Fig. 4.5B).  
  TNF-α, a pro-inflammatory cytokine, is highly expressed in the adipose tissue of obese 
mice [210]. TNF-α is regarded as an important link between obesity and insulin resistance [211]. 
There were significant effects of diet and imidacloprid as well as their interaction on TNFα 
expression (Fig. 4.5C). Mice with high fat diet and imidacloprid at 6 mg/kg bw/day had increased 
TNFα mRNA expression level compared to high fat control (p=0.0029) (Fig. 4.5C). 
 AMPK is known as a master regulator of energy metabolism and activation of AMPK 
leads to the stimulation of fatty acid oxidation and inhibition of lipogenesis [212]. Previously we 
reported that imidacloprid may potentiate adipogenesis via AMPK mediated mechanism in 3T3-
L1 adipocytes [196]. To determine if oral administration of imidacloprid exerts its effect via a 
similar mechanism, we have detected AMPK and its downstream target (acetyl Co-A 
carboxylase, ACC) as well as one of its upstream regulator CaMKKβ [213, 214]. from 
epididymal adipose tissue (Fig. 4.5D-4.5G). There were significant imidacloprid and imidacloprid 
x diet interaction effects without diet effect on the expression of CaMKKβ (Fig. 4.5E). High fat 
diet with imidacloprid (6 mg/kg bw/day) had significantly reduced expression of CaMKKβ 
compared to controls (p= 0.0002) (Fig. 4.5E). There were significant diet and imidacloprid effects 
with interaction on the ratio of expressions of pAMPKα/AMPKα (Fig. 4.5F). High fat diet and 
imidacloprid (6 mg/kg bw/day) fed mice had a significant decrease in the ratio of 
pAMPKα/AMPKα compared to high fat control (p= 0.0028) (Fig. 4.5F). There was only 
imidacloprid effect, without diet effect, on the ratio of phosphorylated ACC/ACC (pACC/ACC) 
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(Fig. 4.5G). Mice treated with imidacloprid at 0.06 and 6 mg/kg bw/day had significantly lower 
pACC/ACC ratios compared to controls (p=0.015 and 0.0403, respectively) (Fig. 4.5G). These 
results suggest that oral administration of imidacloprid might promote adipogenesis via 




Figure 4.5. Effects of imidacloprid on molecular target genes involved in lipid metabolism and 
inflammation in white adipose tissue. Mice were fed with low fat diet or high fat diet 
supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. A. FAT/CD36, 
fatty acid translocase; B. SREBP1c, sterol regulatory element-binding protein-1c; C. TNFα, 
tumor necrosis factor-α; D. Representative pictures; E. CaMKKβ, Ca2+/calmodulin-dependent 
protein kinase kinase β; F. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-
α/AMP-activated protein kinase-α; G. pACC/ACC, phosphorylated acetyl-CoA 
carboxylase/acetyl-CoA carboxylase. Numbers represent mean ± S.E. (n=4-6). Means with 
different letters were significantly different at P<0.05. 
4.3.6 Effects on expression of genes regulating lipid and glucose metabolism as well as 
AMPKα pathway in liver 
 Liver is an important organ in regulating glucose and fatty acid metabolisms, thus, we 
further investigated the effects of imidacloprid and high fat diet on two genes; PEPCK and 
PPARα, which is the rate-limiting enzyme for gluconeogenesis [215] and a key regulator of fatty 
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acid oxidation in liver, respectively [216].  There were significant diet and imidacloprid effects 
with their interaction on the expression of PEPCK (Fig. 4.6A). In mice fed with high fat diet, 
imidacloprid (0.06 and 6 mg/kg bw/day) treatment groups showed significantly higher mRNA 
expression of PEPCK, compared to control (p=0.0166 and 0.0336) (Fig. 4.6A). There were 
significant diet and imidacloprid effects without interaction on PPARα mRNA expression (Fig. 
4.6B). Mice fed imidacloprid at 0.6 and 6 mg/kg bw/day had significantly reduced mRNA 
expression of PPARα compared to controls (p=0.0159 and 0.023, respectively) (Fig. 4.6B). 
   We further investigated the effect of imidacloprid on protein markers important for lipid 
and glucose homeostasis in the liver.  PGC-1α is highly expressed in the liver and is known as a 
master regulator of fatty acid oxidation [217, 218]. Two metabolic sensors, AMPK and SIRT1, 
have been reported to directly increase PGC-1α activity [219]. CaMKKβ is known to be the 
upstream regulator of AMPK [213]. There were significant effects of imidacloprid and 
imidacloprid x diet interaction without significant effect of diet on CaMKKβ expression (Fig. 
4.6D). High fat diet with 6 mg/kg bw/day imidacloprid fed mice had a decrease in expression of 
CaMKKβ compared to high fat control (p=0.0049) (Fig. 4.6D). Significant effects of diet and 
imidacloprid with their interaction were observed for pAMPKα/AMPKα and pACC/ACC ratio 
(Fig. 4.6E & 4.6F). High fat imidacloprid (6 mg/kg bw/day) fed mice exhibited a decreased ratio 
of pAMPKα/AMPKα and pACC/ACC compared to high fat control (p<0.0001 and p=0.0475, 
respectively) (Fig. 4.6E & 4.6F). There were effects of both diet and imidacloprid on SIRT1 and 
PGC-1α expression without interaction (Fig. 4.6G & 4.6H). Mice treated with imidacloprid (0.6 
and 6 mg/kg bw/day) had a significant decrease in expression of SIRT1(p=0.0026 and 0.0121) 
and PGC-1α compared to controls (p=0.0356 and 0.011, respectively) (Fig. 4.6G & 4.6H). These 
results suggest that imidacloprid might contribute to decreased fatty acid oxidation in the liver.  
4.3.7 Effects on expression of genes regulating lipid and glucose metabolism in muscle 
 Muscle is responsible for 70-90% of glucose disposal in our body [220] and insulin 
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resistance in skeletal muscle is the primary defect in type 2 diabetes [221]. In muscle, GLUT4 is 
the main glucose transporter responsible for glucose uptake in response to insulin stimulation 
[222]. It has been reported that mice lacking or overexpressing GLUT4 have a decrease or 
increase in whole-body insulin sensitivity, respectively [223]. In the current study, there were 
significant effects of diet and imidacloprid without interaction on muscle GLUT4 mRNA 
expression (Fig. 4.7A). Mice fed with imidacloprid at 0.06 and 6 mg/kg bw/day had significantly 
lower mRNA expression of GLUT4 compared to controls (p=0.0003 and 0.0012, respectively) 
(Fig. 4.7A).  
  PDK4, a kinase enzyme highly expressed in skeletal muscle, inactivates the enzyme 
pyruvate dehydrogenase [224]. As a result, the pyruvate formed from glycolysis cannot be 
oxidized, which leads to hyperglycemia due to the decrease in blood glucose oxidation [225]. A 
previous study also reported that PDK4 is overexpressed in skeletal muscle of people with type 2 
diabetes, resulting in impaired glucose disposal [226]. In the current mice study, there were 
effects of diet and imidacloprid on PDK4 mRNA expression without interaction (Fig. 4.7B). Mice 
fed with imidacloprid at 6 mg/kg bw/day had higher expression level of PDK4 compared to 
controls (p=0.0015) (Fig. 4.7B).  
  CPT1 is a mitochondrial transmembrane enzyme, recognized as rate limiting for 
mitochondrial fatty acid β-oxidation [227]. In the current study, there was a significant diet effect 
on CPT1 mRNA expression without imidacloprid effect and interaction. Taken together, these 
results suggested that imidacloprid and high fat diet might affect the expression of genes 
important for lipid and glucose metabolism and contribute to adiposity and insulin resistance in 




Figure 4.6. Effects of imidacloprid on molecular target genes regulating lipid and glucose 
metabolism as well as the AMPKα pathway in liver. Mice were fed with low fat diet or high fat   
diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. A. PEPCK, 
phosphoenolpyruvate carboxykinase; B. PPARα, peroxisome proliferator-activated receptor-α; C. 
Representative pictures. D. CaMKKβ, Ca2+/calmodulin -dependent protein kinase kinase β; E. 
pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α /AMP-activated protein 
kinase-α; F. pACC/ACC, phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase; G. 
SIRT1, sirtuin 1; H. PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α. 






Figure 4.7. Effects of imidacloprid on markers regulating lipid and glucose metabolism in muscle. 
Mice were fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg 
bw/day) imidacloprid for 12 weeks. A. GLUT4, glucose transporter type 4; B. PDK4, pyruvate 
dehydrogenase kinase 4; CPT1, carnitine palmitoyltransferase 1. Numbers represent mean ± S.E. 
(n=4-6). Means with different letters were significantly different at P<0.05. 
4.4 Discussion 
 In this study, we demonstrated that dietary exposure to relatively low doses of 
imidacloprid (at or lower than NOAEL) exacerbated high fat diet induced weight gain and insulin 
resistance in C57BL/6J male mice during 12-week treatment. As such, it is the first mouse study 
demonstrating the role of imidacloprid on development of high fat diet induced obesity and type 2 
diabetes. The current results also suggest that imidacloprid may elicit its effects by post-
translational regulation of AMPK via CaMKKβ and/or SIRT1 in adipocytes and the liver. This 
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finding is consistent with our previous reports that imidacloprid inhibits the phosphorylation of 
AMPKα in 3T3-L1 adipocytes [196]. 
 Several studies have reported an interaction between organophosphorous insecticides 
(diazinon and parathion) and high fat diet, including their contribution to increased weight gain 
and insulin resistance [228-232]. Ruzzin et al. [191] reported that persistent organic pollutants 
(POP) in crude fish oil exacerbated high fat diet induced increased visceral adipose tissue and 
insulin resistance compared to refined salmon oil (without POP) in male Sprague-Dawley rats. In 
the Ruzzin study, POP with high fat diet was reported to induce increased liver SREBP1c 
expression. Similarly, imidacloprid exposure increased the expression of SREBP1c in adipose 
tissue in the current study. In addition, our current results showed that imidacloprid with high fat   
diet increased TNFα (a pro-inflammatory cytokine) in adipose tissue of high fat diet fed mice, 
which may have significance in insulin resistance.  
 A previous mice study reported that exposure to DDE initially facilitated high fat diet 
induced hyperglycemia at weeks 4 and 8, which returned to normal at 12-13 weeks [192]. 
However, Ruzzin et al. [191] reported that POP with high fat diet increased HOMA-IR score and 
reduced insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. This report is 
consistent with the current results that imidacloprid with high fat diet increased the blood glucose 
and insulin levels along with impaired insulin resistance. Moreover, we observed that animals fed 
imidacloprid with high fat diet potentiated gluconeogenesis in the liver by targeting PEPCK and 
reduced glucose disposal from the skeletal muscle by decreasing GLUT4 expression and glucose 
oxidation, both of which may have contributed to overall impairment of glucose homeostasis. It is 
important to point out, however, that our results are limited since we did not measure insulin 
stimulated GLUT4 translocation in skeletal muscle. Nevertheless, it was previously reported that 
imidacloprid exposure might induce insulin resistance by reducing insulin stimulated glucose 
uptake, and phosphorylation of protein kinase B (AKT) in adipocytes, hepatocytes and myotubes 
[9]. Thus, it is likely that imidacloprid exacerbated high fat diet induced insulin resistance by 
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targeting insulin signaling pathway. Alternatively, imidacloprid might cause oxidative stress and 
inflammation as previously suggested [233-237]. Inflammation, including the significance of pro-
inflammatory cytokine TNFα, and oxidative stress were reported to be correlated with 
development of obesity and insulin resistance [8, 211, 238, 239]. Inflammation and oxidative 
stress are known to activate JNK (c-Jun N-terminal kinase) [240, 241], which is linked to insulin 
resistance [242]. Thus, further studies of imidacloprid’s role in oxidative stress and inflammation, 
including the role of TNFα, and their contributions to obesity and insulin resistance, are needed to 
understand how imidacloprid elicits altered metabolism. 
 Mice fed with high fat diet showed physiological and metabolic changes compared to low 
fat diet fed mice as expected [243-246]; including increased body weight, calorie intake, serum 
insulin level, HOMA-IR score, expression of epididymal adipose tissue CD36, TNFα, adipocyte 
size and impaired insulin tolerance as well as glucose tolerance. However, several studies 
reported inconsistent results of lipogenesis in mice consuming a high fat diet; increased [247], no 
change [248] or decreased lipogenesis after high fat diet feeding [249, 250]. Our current results 
show no significant different expression levels of SREBP1, a key lipogenic gene, in adipose 
tissue between high fat diet and low fat diet fed mice.  
 Imidacloprid is the most widely used neonicotinoid insecticide [175] and compared to 
highly lipophilic organochlorine and organophosphorus insecticides, imidacloprid is relatively 
water-soluble [185]. Imidacloprid is considered to be moderately toxic, with oral LD50 in rats is 
420 mg/kg body weight, and the typical symptoms of poisoning include fatigue, cramps, and 
muscle weakness [251]. However, the dose we used in the current study was based on NOAEL of 
5.7 mg imidacloprid/kg body weight/day or lower, thus we did not expect any of those acute toxic 
symptoms in these animals [252]. A previous mice study showed that oral gavage of > 5 mg/kg 
bw/day imidacloprid for 28 days resulted in immunosuppressive effects, however no changes in 
body weight were observed for all doses of imidacloprid treatment in that study [177]. Another 
study reported that oral administration of 20 mg/kg bw/day imidacloprid decreased the body 
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weight in rats, however, this was not observed in 10 mg/kg bw/day imidacloprid treated rats 
[193]. Thus, the significance of the current study is the interaction between high fat diet and 
imidacloprid, which would have significance for understanding potential health implications of 
imidacloprid. 
It is known that imidacloprid is quickly absorbed from the gastrointestinal tract and 
distributed in almost all organs and tissues [199]. The oral absorption of imidacloprid was 
estimated as 92-99% [199]. Although imidacloprid intake between low fat diet and high fat diet in 
the current study were not statistically different, we cannot exclude the possibility that high fat 
and low fat diet might have different effects on the bioavailability of imidacloprid, thus leading to 
the differences observed in the current study. Once absorbed, imidacloprid is degraded into a 
variety of metabolites: 6-chloronicotinic acid, imidazolidine 4- and 5- hydroxy compounds, 
olefinic imidacloprid, desnitro-imidacloprid and the nitrosoimine compound [199]. These 
metabolites are known to be excreted mainly in the urine as glutathione and glycine conjugates of 
mercaptonicotinic acid and hippuric acid [199].  Imidacloprid also photo-degrades rapidly in 
water with a half-life of less than 3 hours. However, imidacloprid has been found to be persistent 
in the environment with a photolysis half-life of 39 days at the soil surface (a range of 26.5-229 
days) when absorbed by the soil [185].  
 Despite intensive investigations and establishment of preventive and therapeutic 
strategies for obesity and type 2 diabetes, these diseases have increased significantly in the past 
few decades [253, 254]. Sedentary lifestyle and excessive caloric intake can only partially explain 
the dramatic increase of metabolic diseases worldwide. Recently, air pollution and environmental 
contaminants such as bisphenol A, as well as other POP, are suggested to contribute to the 
development of obesity and insulin resistance [191, 255-257]. Along with the current results, 
these reports provide compelling evidence that environmental contaminants may contribute to the 
epidemic of obesity, insulin resistance and eventually type 2 diabetes. 
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 To conclude, our present finding is the first report that imidacloprid exposure aggravates 
high fat diet induced obesity and insulin resistance in C57BL/6J male mice. The current results 
are significant in substantiating a potential link between insecticide exposure, particularly 
imidacloprid, to dietary fat and adiposity as well as insulin resistance. However, the underlying 
mechanisms by which imidacloprid promotes high fat diet induced obesity and insulin resistance 






IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY IN FEMALE 
C57BL/6J MICE AND ENHANCE ADIPOGENESIS IN 3T3-L1 ADIPOCYTES VIA 
AMPKα-MEDIATED PATHWAY  
5.1 Introduction 
 Among the major classes of insecticides, neonicotinoids are the largest single 
insecticide class on the market currently, representing approximately 27% of global 
insecticide use in 2013 [258]. Since its commercial introduction in 1991, imidacloprid 
has become the most successful neonicotinoid insecticide, representing 41.5% of 
neonicotinoid use [174, 175]. Imidacloprid is used on various of vegetables, grains, and 
turf to control insect pests as well as on pets to control ectoparasitic arthropods [175-
177]. Imidacloprid is also known to be persistent in soil with a photolysis half-life of 39 
days and an aerobic half-life of ~3 years [185]. The above findings suggest a high 
potential for human exposure to imidacloprid. In addition, the use of imidacloprid and 
two other neonicotinoids were restricted by the European Commission in 2013 due to 
their potential role in the collapse of bee populations [43]. 
  Epidemiological studies have suggested a link between persistent organic 
pollutants, including insecticides, and the risk of obesity and its associated pathology[60, 
91, 188-190].  Our previous studies have demonstrated that several pesticides, including 
imidacloprid, promotes adipogenesis in 3T3-L1 adipocytes and induces insulin resistance 
in C2C12 myotubes [6, 9, 196-198]. Our recent publication also reported that oral 
imidacloprid exposure promotes high fat diet-induced adiposity and insulin resistance in 
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male C57 BL/6J mice [259]. It is not known, however, whether imidacloprid exposure 
alone or together with high fat diet will exacerbate obesity and insulin resistance 
symptoms in female mice. Thus, the current study was to determine if oral exposure to 
imidacloprid would aggravate high fat diet-induced adiposity and insulin resistance in 
female C57BL/6J mice. The role of AMPKα in imidacloprid-induced adipogenesis in 
3T3-L1 adipocytes was also determined. 
5.2 Materials and Methods 
5.2.1 Materials 
 3T3-L1 preadipocytes and C2C12 myoblasts were obtained from American Type Culture 
Collection (Manassas, VA). Fetal bovine serum (FBS), horse serum (HS), methylisobutylxanthin, 
insulin, dexamethasone, phosphatase and protease inhibitor cocktail, and 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Imidacloprid (>98%, CAS: 138261-41-3) was obtained from Chem Service Inc. (West 
Chester, PA, USA). Five-week-old female C57BL/6J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA). Semi-purified powdered diets (TD 94048, 4% fat w/w, low 
fat diet and TD 07518, 20% fat w/w, high fat diet) were prepared based on Harlan Laboratories 
(Madison, WI, USA) diets. Food ingredients were purchased from Bio-Serv (Flemington, NJ, 
USA). Serum insulin level was determined with mouse insulin ELISA kit from ALPCO (Salem, 
NH, USA). Non-esterified fatty acid assay kit was purchased from Wako Life Sciences, Inc. 
(Mountain view, CA, USA). Glucose and total cholesterol assay kits were from Genzyme 
Diagnostics (Charlottetown, PE, Canada). Mouse leptin assay kit was from R & D Systems 
(Minneapolis, MN, USA). Mem-PER™ Plus Membrane Protein Extraction Kit, BCA protein kit, 
Infinity™ triglycerides reagent, dichlorodihydrofluorescein diacetate (H2DCFDA), N-acetyl 
cysteine (NAC), and protein A-sepharose 4B conjugate were obtained from Thermo Fisher 
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Scientific (Waltham, MA, USA). Radioimmunoprecipitation assay (RIPA) buffer with 1% 
protease inhibitor was from Boston Bioproducts Inc. (Ashland, MA, USA). Rabbit antibodies for 
mouse acetyl-CoA carboxylase (ACC), phosphorylated ACC (pACC), AMP-activated protein 
kinase α (AMPKα), phosphorylated AMPKα (pAMPKα), and horseradish peroxidase-conjugated 
goat anti-rabbit IgG were obtained from Cell Signaling Technology (Beverly, MA, USA). Rabbit 
antibodies for β-actin were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). 
Rabbit antibody for Ca2+/calmodulin-dependent protein kinase β (CAMKKβ) was purchased from 
Abcam Inc. (Cambridge, MA, USA). Human recombinant insulin (Novolin, 100 U/ml) was 
obtained from Novo Nordisk Pharmaceuticals Industries Inc. (Seattle, WA, USA). Dextrose 
(50%) and bacteriostatic 0.9% sodium chloride solution were from Hospira, Inc. (Lake Forest, IL, 
USA). Dulbecco's Modified Eagle Medium (DMEM), dimethyl sulfoxide (DMSO), and other 
chemicals were from Fisher Scientific (Pittsburgh, PA, USA). 
5.2.2 Animals and diet 
 All animal work was performed using the guidelines approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts under protocol number 
2016-0011. Mice were housed in a humidity and temperature-controlled room with a 12-h 
light/dark cycle. The compositions of diets were as previously described [259]. Water and diet 
were given to mice ad libitum and each changed twice a week. Body weight and food intake were 
monitored weekly. After adaptation, the mice were fed a control diet (4% fat w/w) and subjected 
to baseline insulin tolerance and glucose tolerance tests. Mice were then divided into low fat and 
high fat dietary groups with four imidacloprid treatment doses (0, 0.06, 0.6, and 6 mg/kg bw/day), 
respectively. The treatment lasted for 12 weeks. Doses of imidacloprid were based on previous 
publication [259]; the highest imidacloprid dose was no-observed-adverse-effect-level (NOAEL) 
of imidacloprid at 5.7 mg/kg bw/day and the lowest dose of imidacloprid was estimated average 
daily intake of imidacloprid of 60 µg/kg body weight/day [199-201].  Imidacloprid content in low 
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fat diets were 0, 0.47, 4.7, and 47 mg imidacloprid/kg diet. The content of imidacloprid in high 
fat diets were 0, 0.636, 6.36, and 63.6 mg imidacloprid/kg diet. At the end of the study, the 
average imidacloprid consumption was 0, 0.07, 0.69, and 6.69 mg/kg bw/day in low fat dietary 
groups and 0, 0.08, 0.74, and 6.66 mg/kg bw/day in high fat dietary groups. There were no 
differences in imidacloprid intakes between low vs. high fat diet groups at the same doses. 
 At the end of the experiment, mice were fasted for 4 h before being sacrificed by CO2 
asphyxiation. Blood was collected by cardiac puncture and then centrifuged at 2000 g for 20 
minutes to collect serum. Part of omental adipose tissue was first fixed in 10% phosphate-
buffered formalin, and then used for paraffin sectioning [204]. The adipocyte size was measured 
as previously described [259]. The other parts of the omental adipose tissue and all other organs 
were snap frozen with liquid nitrogen and kept at -80 C. The levels of total non-esterified fatty 
acids (NEFA), leptin, cholesterol, triglyceride (TG), and insulin in serum were determined with 
commercial kits following the manufacturers’ instructions. The homeostasis model assessment- 
insulin resistance (HOMA-IR) score, insulin tolerance test (ITT), glucose tolerance test (GTT) 
were performed as previously described [259]. 
5.2.3 Serum parameters 
 The levels of total cholesterol, leptin, non-esterified fatty acids (NEFA), triglyceride (TG) 
and insulin in serum will be determined with commercial kits following the manufacturers’ 
instructions. 
5.2.4 Insulin tolerance test 
Insulin tolerance test (ITT) will be performed during adaptation and treatment at week 5 
and week 9 as previously described [202]. All mice will be fasted for 4 h. Blood glucose from the 
tail vein will be measured at 0, 15, 30, 60 and 120 min post intraperitoneal injection of insulin 
solution (0.75 U/kg body weight), with a blood glucose meter, Advocate Redi-Code+ (Advocate 
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Meters Inc., Dorado, Puerto Rico). The areas under the curve (AUC) will be calculated with 
Sigma Plot 11.0 (Systat Software, Inc., San Jose, CA, USA). 
5.2.5 Glucose tolerance test 
 Glucose tolerance tests (GTT) will be performed during adaptation and treatment at week 
6 and week 11 as described previously [202]. All mice will be fasted for 6 h before the first 
measurement of blood  glucose from the tail vein and blood glucose will be measured with a 
blood glucose meter (0 min). Then, 20% glucose solution (2 g glucose/kg of body weight) will be 
administered intraperitoneally and blood glucose levels will be further monitored at 15, 30, 60, 
and 120 min. Blood insulin level will be measured at 0, 30, 60 and 120 min with mouse insulin 
ELISA kit from ALPCO (Salem, NH, USA). AUC will be calculated with Sigma Plot. The 
homeostasis model assessment- insulin resistance (HOMA-IR) score will be calculated with 
HOMA-IR calculator (University of Oxford) [203].  
5.2.5 Adipocyte size measurement 
 Epididymal adipose tissue will be fixed in 10% phosphate-buffered formalin and 
processed for paraffin sectioning [204]. Tissue sections (4 µm) will be cut and stained with 
hematoxylin and eosin (HE) staining. Pictures will be taken with Olympus CK2 inverted 
microscope (Olympus, Tokyo, Japan) (100 x magnification) and microscope eyepiece camera 
(AmScope, Irvine, CA). Adipocyte size will be measured as previously described with Image J 
software with minor modification [205]. Mean area of 50 cells from each sample will be 
measured with Image J software. Briefly, the pictures of calibration slide (AmScope, Irvine, CA) 
will be taken under the same settings as the tissue sections and will be used to set the scale in 
image J, then the area of the adipocytes will be measured with Image J. 
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5.2.6 mRNA expression analysis 
 Total RNA were extracted as previously described.[259] Tumor necrosis factor α (TNF-
α) and 18S ribosomal RNA (18S rRNA) were analyzed. Real-time polymerase chain reaction 
(PCR) was performed as previously described [259]. Mm00443258_m1 (TNFα) and 
Mm03928990_g1 (18S rRNA) taqman probe-based gene expression assay kits were from Thermo 
Fisher Scientific (Waltham, MA, USA).   
5.2.7 Immunoprecipitation and immunoblotting 
 Proteins from mouse tissues were extracted, quantified and immunoblotted as previously 
described [198, 259]. For the detection of the phosphorylation of serine 307 on insulin receptor 
substrate (IRS1) (p-IRS1), cell lysates (500 µg of protein) were immunoprecipitated with IRS1 
and protein G beads overnight at 4 °C before immunoblotting.   
5.2.8 Cell culture 
 3T3-L1 preadipocytes were cultured and differentiated as previously described [198]. 
3T3-L1 cells were maintained in DMEM with 10% FBS at 37°C. Two days after confluence (day 
0), cells were differentiated into adipocytes with a mixture of methylisobutylxanthin (0.5 mM), 
dexamethasone (1 µM), and insulin (1 µg/mL) in DMEM containing 10% FBS. On day 2, the 
medium was replaced with DMEM with 10% FBS and insulin (1 µg/mL). Starting from day 4, 
medium was changed with DMEM containing 10% FBS every two days until day 8. 3T3-L1 cells 
were treated with imidacloprid (10 µM) or AICAR (40 µM) for 8 days by adding stock solution 
of imidacloprid or AICAR in dimethyl sulfoxide, both in DMSO, with all treatments having a 
final concentration of 0.02% DMSO. The concentration of imidacloprid and AICAR were based 
on our previous studies [9, 196, 198]. 
 C2C12 cells were maintained in DMEM with 10% FBS at 37 °C. When the cells reach 
80% confluence, they were differentiated into myotubes in DMEM with 2% horse serum for 6 
 73 
days. The myotubes were pre-treated with or without NAC (10 mM) for 30 min [260] and then 10 
µM imidacloprid was added for additional two days.  
5.2.9 Determination of cellular oxidative status 
 We measured cellular oxidative status based on a previous method [261], where the 
nonfluorescent dye H2DCFDA is converted to the highly fluorescent 2',7'-dichlorofluorescein 
(DCF) after being oxidized by various oxidants [261].  After imidacloprid treatments, cells were 
incubated with 10 µM H2DCFDA for 30 minutes. Cells were washed three times with PBS, 
immediately harvested and lysed with RIPA buffer. The fluorescence of the cell lysate 
supernatant was determined at excitation/emission 485/520 nm with SpectraMax 
spectrophotometer (Molecular Devices, Sunnyvale, CA). The fluorescence was then normalized 
to the protein concentration of the cell lysate supernatant as measured by the BCA protein kit. 
5.2.10 Statistical analyses 
 PROC MIXED procedure was utilized to analyze data with the SAS software (Version 
9.3, SAS Institute Inc., Cary, NC, USA). For the result of body weight (Figure 6.1A), two-way 
repeated measure Analysis of Variance (ANOVA) and the slice option in the Least Square (LS) 
means statement were used to determine the differences at each time point. For all other results in 
mice, two-way ANOVA along with LS means statement was used. The Tukey-Kramer’s method 
was applied for the multiple comparisons among the groups. If there were significant interactions 
between diet and imidacloprid, letters were used in the figures to present the differences between 
each group. When there were no interactions between diet and imidacloprid, brackets were used 
in the figures to represent differences between imidacloprid treatments and control groups. Cell 
culture data (Fig. 6.5 & 6.6) were analyzed by one-way ANOVA followed by PROC mixed with 
LS means statement. Tukey’s test was used for the multiple comparisons among the groups. 
P<0.05 were considered as statistically significant.   
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5.3 Results 
5.3.1 Imidacloprid enhanced body weight gain and adipocyte size in high fat diet-fed mice 
  Overall, there were significant effects of dietary fat, imidacloprid, time, and their 
interactions (imidacloprid x diet x time) on body weight (Fig. 5.1A). Both dietary fat and 
imidacloprid had significantly increased body weight gain with a significant interaction between 
dietary fat and imidacloprid (Fig. 5.1B, 133% increase in high fat compared to low fat diet and 
10% increase in imidacloprid treatments compared to the controls). No differences in body 
weight gain were observed among any of the groups in low fat diet-fed mice (Fig. 5.1A). In high 
fat diet-fed mice, imidacloprid (0.6 mg/kg bw/day) resulted in a significant increase in body 
weight compared to the control group starting from week 5 and maintained this trend throughout 
the experiment (~15-22% increase compared to the controls, P<0.05 for all weeks from 5 to 12) 
(Fig. 5.1A). Among high fat diet-fed groups, imidacloprid at 0.6 mg/kg bw/day treatment group 
had greater weight gain, 71% increase compared to the high fat diet-fed control (P=0.0167) (Fig. 
5.1B).   
 The calorie consumption of mice is shown in Fig. 5.1C.  Both dietary fat and 
imidacloprid significantly affected the calorie intake without interaction. High fat diet-fed mice 
consumed 12% more calorie than mice fed on low fat diet (Fig. 5.1C) and imidacloprid fed mice 
have 6% decrease in calorie intake compared to mice in the control groups. However, mice fed 
with 6 mg/kg bw/day imidacloprid had 12% less calorie intake compared to the control groups 








Figure 5.1. Effects of imidacloprid on body weight, body weight gain, adipocyte size and food 
intake. Mice were fed with low or high fat diet supplemented with imidacloprid (0, 0.06, 0.6, and 
6 mg/kg bw/day) for 12 weeks. (A) Body weight was monitored weekly; (B) Body weight gain 
over 12 weeks; (C) Total calorie intake; (D) Representative pictures of epididymal adipose tissues 
after H&E staining (100 x magnifications); (E) Adipocyte size. The mean area of 50 cells from 
each sample were measured with image J. Numbers are mean ± S.E. (n=5-7 for A, B, D, and n=3-





5.3.2 Effects of imidacloprid on organs and tissue weights 
 Organs and tissues weights are shown in Table 5.1. There was a significant dietary fat 
effect, but neither an imidacloprid effect nor their interactions were evident on liver, heart, spleen, 
and kidney weights. Neither dietary fat nor imidacloprid treatments resulted in any effects on 
pancreas. There were significant effects of dietary fat and imidacloprid treatments and with their 
interactions on omental and total adipose tissue weights (92-98% increase in high fat compared to 
low fat diet and 11-17% increase in imidacloprid treatments compared to the controls). In mice 
fed with high fat diet, animals treated with imidacloprid (0.6 mg/kg bw/day) had greater omental 
(45% increase, P=0.0416) and total adipose tissue weights (40% increase, P=0.0391) when 
compared with the control group.   
 Histological analysis revealed significantly increased effects of both dietary fat and 
imidacloprid treatments and with their interaction on omental adipocyte size (52% increase in 
high fat compared to low fat diet and 17% increase in imidacloprid treatments compared to the 
controls, Fig. 5.1D & 5.1E). Compared with the high fat diet-fed control group, imidacloprid (0.6 
mg/kg bw/day) treatment markedly increased adipocyte size (45% increase, P=0.0063) in the 




Table 5.1. Organ Weights (% of body weight) 
 
Low fat diet  High fat diet  
P-value 
 Imidacloprid (mg/kg BW/day)   Imidacloprid (mg/kg BW/day)  




Liver 4.04 ± 0.27 4.45 ± 0.35 4.56 ± 0.17 4.87 ± 0.25  3.45 ± 0.26 3.63 ± 0.16 3.79 ± 0.13 3.36 ± 0.15  <0.0001 n.s. n.s. 
Heart 0.52 ± 0.02 0.54 ± 0.03 0.50 ± 0.01 0.48 ± 0.01  0.47 ±0.03 0.46 ± 0.02 0.40± 0.02 0.42 ± 0.03  <0.0001 n.s. n.s. 
Spleen 0.37 ± 0.03 0.43 ± 0.07 0.35 ± 0.01 0.36 ± 0.02  0.37 ± 0.04 0.31 ± 0.01 0.26 ± 0.01 0.29 ± 0.01  0.017 n.s. n.s. 
Kidney 1.30 ± 0.06 1.31 ± 0.08 1.27 ± 0.02 1.19 ± 0.02  1.17 ± 0.05 1.15 ± 0.05 1.05 ± 0.03 1.09 ± 0.04  0.0002 n.s. n.s. 
Pancreas 1.04 ± 0.09 1.06 ± 0.08 0.96 ± 0.04 0.93 ± 0.03  1.06 ± 0.16 0.93 ± 0.10 0.82 ± 0.05 0.85 ± 0.04  n.s. n.s. n.s. 
Adipose tissue              
Omental 3.00 ± 0.28c  2.82 ± 0.23c 2.60 ± 0.27c 3.34 ± 0.51bc  4.62 ± 0.38b 4.71 ± 0.69ab 6.69 ± 0.39a 6.63 ± 1.19a  <0.0001 0.010 0.0375 
Subcutaneous 2.45 ± 0.19abc 2.32 ± 0.17c 2.22 ± 0.24c 2.24 ± 0.39c  4.26 ± 0.41a 4.22 ± 0.68ab 5.89± 0.31a 5.69 ± 0.38a   <0.0001 n.s. 0.029 
Retroperitoneal 1.01 ± 0.13 0.91 ± 0.17 0.90 ± 0.13 1.34 ± 0.18   2.16 ± 0.21  2.10 ± 0.39  2.93 ± 0.16  2.82 ± 0.12   <0.0001 n.s. n.s. 
Mesenteric 0.88 ± 0.15 0.80 ± 0.09 0.81 ± 0.12 1.07 ± 0.16  1.47 ± 0.16 1.50 ± 0.35 2.03 ± 0.19 1.80 ± 0.15  <0.0001 n.s. n.s. 
Total  7.34 ± 0.85cd  6.85 ± 0.35d 6.53 ± 0.81d 
7.99 ± 
0.97bcd 
 12.5 ± 1.25b  10.0 ± 3.09bc  17.5 ± 1.06a 16.9 ± 1.08a   <0.0001 0.026 0.028 
Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-7). 




Table 5.2. Serum Parameters 
 
Low fat diet  High fat diet  
P-value 
 Imidacloprid (mg/kg BW/day)   Imidacloprid (mg/kg BW/day)  






154.3 ± 27.1  139.9 ± 23.7 145.1 ± 10.1 144.3 ± 5.9  152.5 ± 15.1 150.9 ± 13.2 170.6 ± 9.3 141.9 ± 9.4  n.s. n.s. n.s. 
Insulin 
(ng/mL) 
0.70 ± 0.09 0.79 ± 0.13 0.62 ± 0.08 1.14 ± 0.18  1.02 ± 0.10 1.00 ± 0.21 1.19 ± 0.25 1.45 ± 0.14  0.0025 0.0269 n.s. 
Leptin  
(ng/mL) 
16.1 ± 5.0  19.8 ± 4.2  12.3 ± 3.8  29.1 ± 6.8   36.8 ± 5.0  47.7 ± 21.7  52.5 ± 4.0  69.7 ± 11.0   <0.0001 0.0387 n.s. 
TG 
(mg/dL) 
63.1 ± 1.9 83.7 ± 7.2 75.3 ± 7.2 73.0 ± 3.8  59.9 ± 5.1 67.9 ± 3.7 66.3 ± 1.5 73.1 ± 2.1  0.0378 0.0343 n.s. 
Cholesterol 
(mg/dL) 
65.3 ± 4.9 73.0 ± 6.5 71.3 ± 3.6 62.4 ± 5.2  73.1 ± 2.4 68.6 ± 2.8 89.3 ± 8.3 84.8 ± 8.5  0.0098 n.s. n.s. 
NEFA 
(mEq/L) 
1.3 ± 0.3 1.5 ± 0.3 1.3 ± 0.3 1.0 ± 0.1  1.2 ± 0.2 1.3 ± 0.1 1.4 ± 0.2 1.8 ± 0.4  n.s. n.s. n.s. 
Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-7). Means with different superscripts within the same row are significantly 
different at P<0.05. Abbreviations: n.s., not significant; TG, triglyceride; NEFA, non-esterified fatty acid.  
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5.3.3 Effects of imidacloprid on serum markers 
 Analyses of serum markers are shown in Table 5.2. There were significant effects of both 
dietary fat and imidacloprid treatments (without interaction) on serum insulin, leptin, and TG 
levels. There were 43% increase for insulin, 167% increase for leptin, and 9% decrease in high fat 
over low fat diet fed mice. There were 20% increase for insulin, 46% increase for leptin, and 19% 
increase in imidacloprid treatments over the controls. Mice treated with 6 mg imidacloprid/kg 
bw/day had higher blood insulin and leptin levels compared with the respective control groups 
(50% and 87% increase with P=0.0363 and 0.0271, respectively). Mice fed with imidacloprid 
(0.06 mg/kg bw/day) had higher levels of TG (23% increase, P=0.0458) than the control groups. 
Dietary fat, but not imidacloprid, had significant effects on cholesterol levels (16% increase in 
high fat compared to low fat diet groups). Neither dietary fat nor imidacloprid had any effect on 
serum glucose or NEFA levels in the current study.  
 
5.3.4 Influence of imidacloprid on glucose homeostasis 
 The effects of treatment with imidacloprid or dietary fat on glucose homeostasis were 
determined by ITT, GTT, and HOMA-IR (Fig. 5.2). There were no significant differences of the 
ITT values between any of the groups over time as shown in Fig. 5.2A-5.2C. There was a 
significant effect of dietary fat on GTT values in weeks 6 & 11 (7% and 19% increase in high fat 
groups compared to low fat groups, respectively), without imidacloprid or interaction effects (Fig. 
5.2E & 5.2F).  
5.3.4 Effects of imidacloprid on AMPKα pathway and TNFα in white adipose tissue 
 AMPK is a master regulator of energy metabolism and AMPK activation results in the 
inhibition of lipogenesis [212]. Based on previous publications [196, 259], we have determined 
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the effects of imidacloprid and high fat diet on AMPK, one of its downstream markers (acetyl 
Co-A carboxylase, ACC) and one of its upstream regulators (Ca2+/calmodulin-dependent protein 
kinase β, CaMKKβ) [213, 214] from omental adipose tissue (Fig. 5.3A-5.3D). There were both 
dietary fat and imidacloprid effects on the expression of CaMKKβ without interaction (20% 
decrease in high fat compared to low fat diet and 18% decrease in imidacloprid treatments 
compared to the controls, Fig. 5.3A). Imidacloprid (0.6 and 6 mg/kg bw/day) had reduced 
expression of CaMKKβ compared to controls (21% and 24% reduction with P= 0.0099 and 
0.0023, respectively) (Fig. 5.3A). There were significant effects of imidacloprid and imidacloprid 
& dietary fat interaction on the ratio of pAMPKα/AMPKα (7% decrease in high fat compared to 
low fat diet and 22% decrease in imidacloprid treatments compared to the controls, Fig. 5.3B). 
High fat diet and imidacloprid (0.6 and 6 mg/kg bw/day) fed mice had significantly decreased 
ratio of pAMPKα/AMPKα compared to high fat diet-fed control (45% and 58% reduction with 
P= 0.0064 and 0.0002, respectively) (Fig. 5.3B). There were dietary fat and imidacloprid as well 
as their interaction effects on the ratio of phosphorylated ACC/ACC (pACC/ACC) (14% decrease 
in high fat compared to low fat diet and 16% decrease in imidacloprid treatments compared to the 
controls, Fig. 5.3C). High fat diet fed mice treated with imidacloprid at 0.06 and 6 mg/kg bw/day 
had significantly lower pACC/ACC ratios compared to high fat diet-fed control (48% and 43% 
reduction with P=0.0061 and 0.0172, respectively) (Fig. 5.3C). The current results indicate that 
oral administration of imidacloprid enhance lipogenesis in part via AMPKα dependent pathway 
in mice white adipose tissue. 
 There were dietary fat and imidacloprid as well as their interaction effects on TNF-α 
mRNA level (127% increase in high fat compared to low fat diet and 70% increase in 
imidacloprid treatments compared to the controls, Fig. 5.3E). High fat diet-fed mice treated with 
imidacloprid at 0.6 and 6 mg/kg bw/day had significantly higher levels of TNFα compared to 
high fat diet-fed controls (165% and 182% increase, respectively, with P<0.0001 for both) (Fig. 




Figure 5.2. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance test 
(GTT) (D, E, F) as determined as the area under the curve (AUC) and HOMA-IR (G). Mice were 
fed with low or high fat diet supplemented with imidacloprid (0, 0.06, 0.6, and 6 mg/kg bw/day) 
for 12 weeks. ITT was measured during adaptation period, weeks 5 and 9. GTT was measured 
during adaptation period, weeks 6 and 11. Blood was collected from the tail vein, and glucose 
levels were determined at 0 min.  Insulin (ITT) or glucose solutions (GTT) were subsequently 
administered by intraperitoneal injection and glucose level were further measured at 15, 30, 60 
and 120 min post injection. HOMA-IR score was calculated at week 12 with HOMA-IR 







Figure 5.3. Effects of imidacloprid on AMPKα pathway and TNFα expression in the white 
adipose tissue. Mice were fed with low or high fat diet supplemented with imidacloprid (0, 0.06, 
0.6, and 6 mg/kg bw/day) for 12 weeks. A. CaMKKβ, Ca2+/calmodulin-dependent protein kinase 
β; B. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated protein 
kinase-α; C. pACC/ACC, phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase; D. 
Representative pictures; E. TNFα, tumor necrosis factor α. Numbers represent mean ± S.E. (n=4-
6). Means with different letters were significantly different at P<0.05. 
5.3.4 Effects of AMPKα activation on imidacloprid induced adipogenesis 
 To further determine the role of AMPKα activation on imidacloprid-induced 
adipogenesis, 3T3-L1 adipocytes were co-treated with imidacloprid and AICAR, an AMPK 
activator [198]. Consistent with results in Fig. 5.3 and the previous report [196], imidacloprid 
treatment alone increased fat accumulation compared to control group (P=0.0012) (Fig. 5.4A). 
AICAR treatment alone decreased fat accumulation (P<0.0001) as expected [198]. However, co-
treatment of AICAR and imidacloprid resulted in significantly decreased fat accumulation to a 
level similar to AICAR alone (P=0.0012, compared to control). Consistently as AMPK activation 
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was reported to decrease the expression of Fig. 5.4B-5.4D further shows that AICAR and 
imidacloprid co-treatment significantly decreased the expression of C/EBPα (P<0.0001), while 
increase the ratio of pAMPKα/AMPKα to the level similar to AICAR alone. These findings are 
consistent with previously reported findings where AMPK activation was reported to decrease the 
expression of C/EBPα [163]. These results suggest that imidacloprid promotes adipogenesis via 
the AMPKα-mediated pathway in 3T3-L1 adipocytes.    
 
Figure 5.4. Influence of AMPKα activation on adipogenesis induced by imidacloprid in 3T3-L1 
adipocytes. A. Triglyceride; B. Representative pictures; C. C/EBPα, CAATT element binding 
protein-α; D. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated 
protein kinase-α. Cells were treated with imidacloprid (10 µM) or AICAR (40 µM) for 8 days. 
Numbers represent mean ± S.E. (n=3). Means with different letters were significantly different at 
P<0.05. 
5.3.5 Effects of imidacloprid on insulin signaling pathway in C2C12 myotubes 
 Phosphorylation of IRS1 Serine 307 (pIRS1 S307) is associated with the inhibition of 
insulin signaling [262]. Figure 6.5A & 6.5B showed that imidacloprid significantly decreased 
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insulin-stimulated phosphorylation of protein kinase B (AKT), while increasing the 
phosphorylation of IRS1 S307. Imidacloprid (10 µM) was further observed to elevate the 
oxidative stress (Fig. 5.5C), and NAC, an oxygen free radical chelator [263], partially reversed 
the decreased phosphorylation of AKT induced by imidacloprid (Fig. 5.5D). These results 
suggest that the elevated cellular oxidative stress is partially responsible for insulin resistance 
induced by imidacloprid. 
 
 
Figure 5.5. Effects of imidacloprid on insulin signaling and oxidative stress in C2C12 myotubes. 
A. pAKT/AKT, phosphorylated AKT/AKT; B. pIRS1/IRS1, phosphorylated insulin receptor 
substrate 1 (Serine 307)/insulin receptor substrate 1; C. Effects of imidacloprid on the oxidative 
stress; D. N-acetyl cysteine (NAC, 10 mM) partially restored imidacloprid induced decrease of 
pAKT. Immunoprecipitation was first performed with IRS1 antibody and then immunoblotted 
with pIRS1 or IRS1 antibodies. Cells were differentiated into myotubes for 6 days in DMEM 
with 2% horse serum and then myotubes were treated with imidacloprid (10µM) for 2 days. One 
day before insulin stimulation, media were changed to F-12K with 2% horse serum. Protein 
expression was determined after treatment with or without insulin (100 nM) for 15 minutes. 




 In the current in vivo study, oral exposure to imidacloprid at or lower than the NOAEL, 
aggravated high fat diet-induced weight gain and elevated serum insulin levels in C57BL/6J 
female mice. The current in vitro results indicate that imidacloprid may elicit these effects by 
post-translational regulation of AMPK pathway in white adipose tissue. Although we did not 
observe any significant effect of imidacloprid on insulin resistance in the current female study, 
imidacloprid might induce insulin resistance via TNFα and/or oxidative stress-mediated 
mechanism as seen in previous male study [259].  
 Previously oral administration of imidacloprid to mice or rats at 15 or 20 mg/kg bw/day 
significantly decreased body weight, whereas mice exposed to 5 or 10 mg/kg bw/day showed no 
change in body weight when fed chow diet (low fat diet) [193, 264]. Our previous publication 
first reported the interaction between oral imidacloprid administration (at lower than 6 mg/kd 
bw/day) and high fat diet in male mice, resulting in significantly induced weight gain in male 
mice [259]. We now show that imidacloprid and high fat diet significantly induced weight gain 
also in female mice. There is only one other study reporting the role of high fat diet potentiating 
the effect of environmental contaminants on weight gain where persistent organic pollutants 
(POP) in crude fish oil were reported to potentiate high fat diet (20% wt/wt corn oil)-induced 
visceral adipose tissue and weight gain compared with refined salmon oil (without POP) after 4 
weeks in male Sprague-Dawley rats [191]. This study failed, however, to compare the role of 
POP in low fat diet. Therefore, it was not clear if high fat diet contributed to the effects of POP in 
this model. Thus, the significance of the current study and our previous male study is the 
interaction between low dose imidacloprid (at or lower than an NOAEL of 5.7 mg 
imidacloprid/kg bw/day) and high fat diet on the development of obesity. The current results 
further support that effects of imidacloprid and high fat diet on weight gain was independent of 
the sex of mice. Although the mechanism of how high fat diet induces increased weight gain 
following imidacloprid treatment is still unknown, we speculate that high-fat diet and 
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imidacloprid interaction is independent of type of fat used, because both the current study 
(soybean oil used) and study from Ruzzin et al. (2010) (corn oil used) observed similar weight 
gain by treatment and high fat diets. It is possible that high fat diet induces metabolic stress and 
imidacloprid further exacerbate this process, resulting in excess weight gain in high fat diet-fed 
mice. Alternatively, we cannot exclude the possibility that low and high fat diets might have 
different effects on the bioavailability of insecticides, thus leading to the differences observed in 
this study.  
 In addition to high-fat diet induced weight gain, Ruzzin et al [191] also reported that 
persistent organic pollutants (POP) in crude fish oil promoted high fat diet (20% wt/wt corn oil)-
induced insulin resistance compared to refined salmon oil (without POP) in male rats. Others 
have reported that oral administration of 20 mg imidacloprid/kg bw/day for 90 days with chow 
diet (low fat diet) increased blood glucose level, whereas 10 mg imidacloprid/kg bw/day did not 
affect blood glucose in female rats [193]. Our previous study reported that imidacloprid treatment 
(0.6 and 6 mg/kg bw/day for 12 weeks) exacerbated high fat diet (soybean oil)-induced insulin 
resistance in male mice [259]. In the current study, however, the 12-week imidacloprid exposure 
significantly increased serum insulin levels without influence on insulin tolerance and glucose 
tolerance in high fat diet-fed female mice. These findings suggest a potential sex differences in 
susceptibility to high fat diet-induced insulin resistance. It is possible that compared with male 
mice, female mice may require longer time, and/or higher treatment doses to develop metabolic 
disorders under the experimental conditions used. In support of this contention, others have 
reported that female mice were resistant to high fat diet-induced glucose intolerance and insulin 
resistance [265], which may be due to estrogens that are protective against the development of 
metabolic syndrome and insulin resistance in female rodents [266].   
  In the previous male study [259], there were interactions between imidacloprid and 
dietary fat on CaMKKβ expression and AMPK phosphorylation in adipocytes. In the current 
study, however, there is only an interaction between imidacloprid and dietary fat on AMPK 
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phosphorylation, but not on CaMKKβ expression. Thus, whether imidacloprid affects AMPKα 
activation via CaMKKβ or other upstream regulators in high fat diet-fed female mice needs to be 
further determined. In addition, imidacloprid is an agonist on nicotinic acetylcholine receptors at 
low concentrations, but blocks them at high concentrations [39]. It is not clear from the results of 
the current study whether imidacloprid induces adipogenesis and/or insulin resistance by way of 
or independent of its action on nicotinic acetylcholine receptors in muscle or adipose tissue. 
 Imidacloprid (10 µM) exposure was previously reported to induce insulin resistance by 
reducing both insulin-stimulated glucose uptake and phosphorylation of AKT in myotubes [9]. 
Imidacloprid was also reported to increase TNF-α, Interleukine-1β, and Interleukine-6 in mice 
liver and brain [233]. TNFα is a proinflammatory cytokine released mainly from macrophages in 
response to other physiological processes [267] and is known to inhibit insulin signaling by 
activating protein tyrosine phosphatase by removing tyrosine phosphate groups from IRS-1 [267]. 
In addition, binding of TNFα to its receptors triggers a broad pattern of signaling cascades, 
including c-Jun amino-terminal kinase (JNK), which cause insulin resistance by promoting serine 
phosphorylation of IRS1 at 307, a negative regulator of insulin signaling [267]. In the current 
study, imidacloprid increased TNFα expression in adipose tissue, which might contribute to 
developing insulin resistance by imidacloprid.  
 Chronic oxidative stress is thought to be one of contributing factors to the development of 
chronic diseases, including insulin resistance [268]. Oxidative stress was reported to stimulate the 
serine kinase of p38 mitogen-activated protein kinase (p38 MAPK), which is correlated with 
reduced insulin signaling and glucose transport [269]. Imidacloprid was previously reported to 
cause oxidative stress [233, 234],  and our current results from C2C12 muscle cells suggest that 
imidacloprid reduces insulin-stimulated phosphorylation of AKT, partially mediated by oxidative 
stress, further supporting the potential role of oxidative stress on imidacloprid’s effects on insulin 
responsiveness. However, the in vivo effect of imidacloprid on insulin responsiveness, especially 
in females, needs to be further determined.  
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 Imidacloprid is readily absorbed from the gastrointestinal tract and distributed in almost 
all tissues [199].  Once absorbed, imidacloprid is degraded into several metabolites [199] and 
excreted in the urine as glutathione and glycine conjugates of mercaptonicotinic acid and hippuric 
acid [199].  Imidacloprid is regarded as moderately toxic, with oral LD50 of 420 mg/kg bw in rats, 
and the typical symptoms of poisoning include cramps, fatigue, and muscle weakness, which 
were not observed in the current study due to low doses used [252].  
 In conclusion, the current study reports that imidacloprid exposure (0.6 and 6 mg/kg 
bw/day) promotes high fat diet-induced obesity in female C57BL/6J mice. Although the detailed 
mechanisms on how imidacloprid interacted with high fat diet still needs to be clarified, the 
results are significant in demonstrating a potential link between low level imidacloprid exposure 




FUTURE DIRECTIONS  
 The current results showed that both fipronil and imidacloprid promoted adipogenesis via 
AMPKα-mediated mechanism in 3T3-L1 adipocytes. Whether fipronil and imidacloprid directly 
targets AMPKα or through regulating other upstream markers or receptors need to be further 
confirmed. Both fipronil and imidacloprid have been reported to increase intracellular calcium 
concentrations in neuron cells [165, 270]. Based on reports that chronic elevation of intracellular 
calcium might impair the activation of AMPK via calcium/calmodulin kinase kinase-β 
(CaMKKβ) [166, 167] as well as induce insulin resistance [271],  it is possible that fipronil and 
imidacloprid may influence intracellular calcium levels, leading to altered adipogenesis via 
CaMKKβ- and AMPK-mediated mechanisms as well as insulin resistance. This contention is 
supported by the fact that imidacloprid decreased the expression of CaMKKβ in adipose tissue, 
although fipronil’s effect on CaMKKβ remained to be determined. Fipronil and imidacloprid’s 
effect on intracellular calcium in adipocytes and myotubes need to be further elucidated to 
determine the underlying mechanisms of fipronil and imidacloprid on development of obesity and 
insulin resistance.   
 Imidacloprid increased body weight gain and adiposity only in high fat diet-fed mice, but 
not in low fat diet-fed mice. Currently, limited knowledge is known about how dietary fat 
contributed to imidacloprid’s effect on obesity. It is possible that low and high fat diets might 
have different effects on the bioavailability of insecticides, thus leading to the differences 
observed in this study. It is also possible that high fat diet has given the mice metabolic stress and 
imidacloprid further exacerbate this process. Further investigation on the absorption and 
accumulation efficacy of imidacloprid when delivered orally in low-fat and high-fat diet are 
needed.  
 Imidacloprid treatment resulted in sex-dependent responses on glucose metabolism. 
Although it is not clear how sex differences affected imidacloprid’s effect on insulin resistance, it 
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is possible that female mice may be more resistant to altered insulin responsiveness caused by 
imidacloprid than males as estrogens were known to protect against the development of insulin 
resistance [266].  Further investigation on the role of estrogen in development of insulin 
resistance induced by imidacloprid especially in female mice (for example with estrogen receptor 
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